{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T05:10:59Z","timestamp":1791522659949,"version":"4.3.4"},"reference-count":292,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-03057-w","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:52:54Z","timestamp":1790167974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antibody-drug conjugate engineering: from design to efficacy and safety"],"prefix":"10.1038","volume":"11","author":[{"given":"Alberto","family":"Ocana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9530-2658","authenticated-orcid":false,"given":"Jorge R.","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Alonso-Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bal\u00e1zs","family":"Gy\u0151rffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henry","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4704-8971","authenticated-orcid":false,"given":"Atanasio","family":"Pandiella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"key":"3057_CR1","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13045-023-01519-0","volume":"16","author":"A L\u00f3pez de S\u00e1","year":"2023","unstructured":"L\u00f3pez de S\u00e1, A. et al. Considerations for the design of antibody drug conjugates (ADCs) for clinical development: lessons learned. J. Hematol. Oncol. 16, 118 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"3057_CR2","doi-asserted-by":"publisher","first-page":"12875","DOI":"10.3390\/ijms252312875","volume":"25","author":"C D\u00edaz-Tejeiro","year":"2024","unstructured":"D\u00edaz-Tejeiro, C. et al. Understanding the preclinical efficacy of antibody-drug conjugates. Int J. Mol. Sci. 25, 12875 (2024).","journal-title":"Int J. Mol. Sci."},{"key":"3057_CR3","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1158\/2159-8290.CD-24-0708","volume":"14","author":"R Colombo","year":"2024","unstructured":"Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M. & de Vries, E. G. E. The journey of antibody-drug conjugates: lessons learned from 40 years of development. Cancer Discov. 14, 2089\u20132108 (2024).","journal-title":"Cancer Discov."},{"key":"3057_CR4","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","volume":"22","author":"C Dumontet","year":"2023","unstructured":"Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M. & Beck, A. Antibody-drug conjugates come of age in oncology. Nat. Rev. Drug Discov. 22, 641\u2013661 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3057_CR5","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1056\/NEJMoa2203690","volume":"387","author":"S Modi","year":"2022","unstructured":"Modi, S. et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N. Engl. J. Med. 387, 9\u201320 (2022).","journal-title":"N. Engl. J. Med"},{"key":"3057_CR6","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","volume":"40","author":"R Colombo","year":"2022","unstructured":"Colombo, R. & Rich, J. R. The therapeutic window of antibody drug conjugates: a dogma in need of revision. Cancer Cell 40, 1255\u20131263 (2022).","journal-title":"Cancer Cell"},{"key":"3057_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02489-2","volume":"24","author":"B Chen","year":"2025","unstructured":"Chen, B. et al. Antibody-drug conjugates in cancer therapy: current landscape, challenges, and future directions. Mol. Cancer 24, 279 (2025).","journal-title":"Mol. Cancer"},{"key":"3057_CR8","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","volume":"18","author":"R Wang","year":"2025","unstructured":"Wang, R. et al. Antibody-Drug Conjugates (ADCs): current and future biopharmaceuticals. J. Hematol. Oncol. 18, 51 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"3057_CR9","doi-asserted-by":"publisher","first-page":"258","DOI":"10.3390\/pharmaceutics17020258","volume":"17","author":"P Ballest\u00edn","year":"2025","unstructured":"Ballest\u00edn, P. et al. Understanding the toxicity profile of approved ADCs. Pharmaceutics 17, 258 (2025).","journal-title":"Pharmaceutics"},{"key":"3057_CR10","doi-asserted-by":"crossref","unstructured":"Ocana, A. & Espinosa, J. R. Biophysical considerations for rational antibody and ADC design. Trends Open 1, 236\u2013246 (2026).","DOI":"10.1016\/j.treopn.2026.05.011"},{"key":"3057_CR11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1586\/17512433.2013.827405","volume":"6","author":"P Sapra","year":"2013","unstructured":"Sapra, P., Betts, A. & Boni, J. Preclinical and clinical pharmacokinetic\/pharmacodynamic considerations for antibody-drug conjugates. Expert Rev. Clin. Pharm. 6, 541\u2013555 (2013).","journal-title":"Expert Rev. Clin. Pharm."},{"key":"3057_CR12","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.tips.2024.10.005","volume":"45","author":"V Blay","year":"2024","unstructured":"Blay, V. & Pandiella, A. Strategies to boost antibody selectivity in oncology. Trends Pharm. Sci. 45, 1135\u20131149 (2024).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR13","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nrd.2016.268","volume":"16","author":"A Beck","year":"2017","unstructured":"Beck, A., Goetsch, L., Dumontet, C. & Corva\u00efa, N. Strategies and challenges for the next generation of antibody-drug conjugates. Nat. Rev. Drug Discov. 16, 315\u2013337 (2017).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3057_CR14","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s11684-024-1085-3","volume":"18","author":"A Murmu","year":"2024","unstructured":"Murmu, A. & Gy\u0151rffy, B. Artificial intelligence methods available for cancer research. Front Med. 18, 778\u2013797 (2024).","journal-title":"Front Med"},{"key":"3057_CR15","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1016\/j.tips.2019.06.004","volume":"40","author":"HCS Chan","year":"2019","unstructured":"Chan, H. C. S., Shan, H., Dahoun, T., Vogel, H. & Yuan, S. Advancing drug discovery via artificial intelligence. Trends Pharm. Sci. 40, 592\u2013604 (2019).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR16","unstructured":"Condensate-driven transcriptional reprogramming defines core vulnerabilities in esophageal and gastric cancers | bioRxiv. https:\/\/www.biorxiv.org\/content\/10.64898\/2026.02.23.707358v1.full."},{"key":"3057_CR17","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/s41392-022-00994-0","volume":"7","author":"Y You","year":"2022","unstructured":"You, Y. et al. Artificial intelligence in cancer target identification and drug discovery. Signal Transduct. Target Ther. 7, 156 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"3057_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1329","volume":"13","author":"C Nieto-Jim\u00e9nez","year":"2023","unstructured":"Nieto-Jim\u00e9nez, C. et al. Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates. Clin. Transl. Med. 13, e1329 (2023).","journal-title":"Clin. Transl. Med."},{"key":"3057_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1229575","volume":"14","author":"A Pandiella","year":"2023","unstructured":"Pandiella, A. et al. Considerations for the clinical development of immuno-oncology agents in cancer. Front. Immunol. 14, 1229575 (2023).","journal-title":"Front. Immunol."},{"key":"3057_CR20","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1007\/s10928-012-9276-y","volume":"39","author":"DK Shah","year":"2012","unstructured":"Shah, D. K., Haddish-Berhane, N. & Betts, A. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK\/PD model: a case study with brentuximab-vedotin. J. Pharmacokinet. Pharmacodyn. 39, 643\u2013659 (2012).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"3057_CR21","doi-asserted-by":"publisher","first-page":"3508","DOI":"10.1007\/s11095-015-1626-1","volume":"32","author":"AP Singh","year":"2015","unstructured":"Singh, A. P., Shin, Y. G. & Shah, D. K. Application of pharmacokinetic-pharmacodynamic modeling and simulation for antibody-drug conjugate development. Pharm. Res. 32, 3508\u20133525 (2015).","journal-title":"Pharm. Res"},{"key":"3057_CR22","doi-asserted-by":"publisher","first-page":"100288","DOI":"10.1016\/j.crmeth.2022.100288","volume":"2","author":"SR Upadhya","year":"2022","unstructured":"Upadhya, S. R. & Ryan, C. J. Experimental reproducibility limits the correlation between mRNA and protein abundances in tumor proteomic profiles. Cell Rep. Methods 2, 100288 (2022).","journal-title":"Cell Rep. Methods"},{"key":"3057_CR23","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2016.03.014","volume":"165","author":"Y Liu","year":"2016","unstructured":"Liu, Y., Beyer, A. & Aebersold, R. On the dependency of cellular protein levels on mRNA abundance. Cell 165, 535\u2013550 (2016).","journal-title":"Cell"},{"key":"3057_CR24","doi-asserted-by":"publisher","first-page":"e0121314","DOI":"10.1371\/journal.pone.0121314","volume":"10","author":"D Bausch-Fluck","year":"2015","unstructured":"Bausch-Fluck, D. et al. A mass spectrometric-derived cell surface protein atlas. PLoS One 10, e0121314 (2015).","journal-title":"PLoS One"},{"key":"3057_CR25","doi-asserted-by":"publisher","first-page":"179","DOI":"10.3390\/cancers17020179","volume":"17","author":"S Rahmati","year":"2025","unstructured":"Rahmati, S. & Emili, A. Proximity labeling: precise proteomics technology for mapping receptor protein neighborhoods at the cancer cell surface. Cancers 17, 179 (2025).","journal-title":"Cancers"},{"key":"3057_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2025.101437","volume":"24","author":"JR Thorup","year":"2025","unstructured":"Thorup, J. R. et al. Microscaled cell surface proteomics for cryo-preserved cells and tissue samples. Mol. Cell Proteom. 24, 101437 (2025).","journal-title":"Mol. Cell Proteom."},{"key":"3057_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.786069","volume":"12","author":"A Alcaraz-Sanabria","year":"2021","unstructured":"Alcaraz-Sanabria, A. et al. Transcriptomic mapping of non-small cell lung cancer K-RAS p.G12C mutated tumors: identification of surfaceome targets and immunologic correlates. Front. Immunol. 12, 786069 (2021).","journal-title":"Front. Immunol."},{"key":"3057_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100102","volume":"6","author":"F Schettini","year":"2021","unstructured":"Schettini, F. et al. Identification of cell surface targets for CAR-T cell therapies and antibody-drug conjugates in breast cancer. ESMO Open 6, 100102 (2021).","journal-title":"ESMO Open"},{"key":"3057_CR29","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/2159-8290.CD-21-1429","volume":"12","author":"SM Lim","year":"2022","unstructured":"Lim, S. M., Kim, C. G., Lee, J. B. & Cho, B. C. Patritumab deruxtecan: paving the way for EGFR-TKI-resistant NSCLC. Cancer Discov. 12, 16\u201319 (2022).","journal-title":"Cancer Discov."},{"key":"3057_CR30","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1016\/j.annonc.2024.02.003","volume":"35","author":"HA Yu","year":"2024","unstructured":"Yu, H. A. et al. Translational insights and overall survival in the U31402-A-U102 study of patritumab deruxtecan (HER3-DXd) in EGFR-mutated NSCLC. Ann. Oncol. 35, 437\u2013447 (2024).","journal-title":"Ann. Oncol."},{"key":"3057_CR31","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911498","volume":"12","author":"L Gandullo-S\u00e1nchez","year":"2020","unstructured":"Gandullo-S\u00e1nchez, L. et al. HER3 targeting with an antibody-drug conjugate bypasses resistance to anti-HER2 therapies. EMBO Mol. Med. 12, e11498 (2020).","journal-title":"EMBO Mol. Med."},{"key":"3057_CR32","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1158\/0008-5472.CAN-21-3481","volume":"82","author":"SM Lim","year":"2022","unstructured":"Lim, S. M., Kim, C. G. & Cho, B. C. Antibody-drug conjugates: a new addition to the treatment landscape of EGFR-mutant non-small cell lung cancer. Cancer Res 82, 18\u201320 (2022).","journal-title":"Cancer Res"},{"key":"3057_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/2461257","volume":"2018","author":"J-H Lee","year":"2018","unstructured":"Lee, J.-H. et al. Tumor-shed antigen affects antibody tumor targeting: comparison of two 89Zr-labeled antibodies directed against shed or nonshed antigens. Contrast Media Mol. Imaging 2018, 2461257 (2018).","journal-title":"Contrast Media Mol. Imaging"},{"key":"3057_CR34","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1002\/jps.22801","volume":"101","author":"JJ Rhoden","year":"2012","unstructured":"Rhoden, J. J. & Wittrup, K. D. Dose dependence of intratumoral perivascular distribution of monoclonal antibodies. J. Pharm. Sci. 101, 860\u2013867 (2012).","journal-title":"J. Pharm. Sci."},{"key":"3057_CR35","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/s41567-018-0186-9","volume":"14","author":"J Chin-Hun Kuo","year":"2018","unstructured":"Chin-Hun Kuo, J., Gandhi, J. G., Zia, R. N. & Paszek, M. J. Physical biology of the cancer cell glycocalyx. Nat. Phys. 14, 658\u2013669 (2018).","journal-title":"Nat. Phys."},{"key":"3057_CR36","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","volume":"630","author":"J Abramson","year":"2024","unstructured":"Abramson, J. et al. Accurate structure prediction of biomolecular interactions with AlphaFold 3. Nature 630, 493\u2013500 (2024).","journal-title":"Nature"},{"key":"3057_CR37","doi-asserted-by":"crossref","unstructured":"Noriega, H. A. & Wang, X. S. AI-driven innovation in antibody-drug conjugate design. Front. Drug Discov. 5, (2025).","DOI":"10.3389\/fddsv.2025.1628789"},{"key":"3057_CR38","doi-asserted-by":"publisher","first-page":"3250","DOI":"10.3390\/cancers15123250","volume":"15","author":"L Paniagua-Herranz","year":"2023","unstructured":"Paniagua-Herranz, L. et al. Genomic mapping of epidermal growth factor receptor and mesenchymal-epithelial transition-up-regulated tumors identifies novel therapeutic opportunities. Cancers 15, 3250 (2023).","journal-title":"Cancers"},{"key":"3057_CR39","doi-asserted-by":"publisher","first-page":"6580","DOI":"10.1158\/1538-7445.AM2024-6580","volume":"84","author":"Y Xiao","year":"2024","unstructured":"Xiao, Y. et al. Abstract 6580: a novel EGFR x cMET bispecific ADC PRO1286 demonstrated broad antitumor activity and promising tolerability in preclinical models. Cancer Res. 84, 6580 (2024).","journal-title":"Cancer Res."},{"key":"3057_CR40","doi-asserted-by":"publisher","first-page":"LB279","DOI":"10.1158\/1538-7445.AM2025-LB279","volume":"85","author":"L Wang","year":"2025","unstructured":"Wang, L. et al. Abstract LB279: SDP01873, a novel HER3\u00d7c-Met bispecific antibody-drug conjugate (ADC) targeting EGFR tyrosine kinase inhibitor (TKI)-resistant non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and beyond. Cancer Res. 85, LB279 (2025).","journal-title":"Cancer Res."},{"key":"3057_CR41","doi-asserted-by":"publisher","DOI":"10.1093\/bioadv\/vbae096","volume":"4","author":"E Chekalin","year":"2024","unstructured":"Chekalin, E. et al. Computational discovery of co-expressed antigens as dual targeting candidates for cancer therapy through bulk, single-cell, and spatial transcriptomics. Bioinform. Adv. 4, vbae096 (2024).","journal-title":"Bioinform. Adv."},{"key":"3057_CR42","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/d41573-025-00105-y","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard, A. PD1 \u00d7 VEGF blocking bispecifics for cancer draw big backing. Nat. Rev. Drug Discov. 24, 490 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3057_CR43","doi-asserted-by":"publisher","first-page":"8611","DOI":"10.1200\/JCO.2025.43.16_suppl.8611","volume":"43","author":"E Fontana","year":"2025","unstructured":"Fontana, E. et al. Interim results of PDL1V (PF-08046054), a vedotin-based ADC targeting PD-L1, in patients with NSCLC in a phase 1 trial. J. Clin. Oncol. 43, 8611\u20138611 (2025).","journal-title":"J. Clin. Oncol."},{"key":"3057_CR44","unstructured":"A phase I clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of HLX43 (anti-PD-L1 ADC) in patients with advanced\/metastatic solid tumors. J. Clin. Oncol. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2025.43.16_suppl.3025."},{"key":"3057_CR45","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.ddtec.2018.09.003","volume":"30","author":"A Maruani","year":"2018","unstructured":"Maruani, A. Bispecifics and antibody\u2013drug conjugates: a positive synergy. Drug Discov. Today.: Technol. 30, 55\u201361 (2018).","journal-title":"Drug Discov. Today.: Technol."},{"key":"3057_CR46","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","volume":"14","author":"Y Gu","year":"2024","unstructured":"Gu, Y., Wang, Z. & Wang, Y. Bispecific antibody drug conjugates: making 1+1>2. Acta Pharm. Sin. B 14, 1965\u20131986 (2024).","journal-title":"Acta Pharm. Sin. B"},{"key":"3057_CR47","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/s41392-021-00868-x","volume":"7","author":"S Jin","year":"2022","unstructured":"Jin, S. et al. Emerging new therapeutic antibody derivatives for cancer treatment. Sig Transduct. Target Ther. 7, 39 (2022).","journal-title":"Sig Transduct. Target Ther."},{"key":"3057_CR48","doi-asserted-by":"publisher","first-page":"e70087","DOI":"10.1002\/cncy.70087","volume":"134","author":"B Nelson","year":"2026","unstructured":"Nelson, B. & Faquin, W. Bridging the global diversity gap in cancer genomics: ambitious new collaborations are aiming to create valuable cancer genomics databases that better reflect real-world diversity. Cancer Cytopathol. 134, e70087 (2026).","journal-title":"Cancer Cytopathol."},{"key":"3057_CR49","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1038\/s43018-021-00282-w","volume":"2","author":"Z Hu","year":"2021","unstructured":"Hu, Z. et al. The Cancer Surfaceome Atlas integrates genomic, functional and drug response data to identify actionable targets. Nat. Cancer 2, 1406\u20131422 (2021).","journal-title":"Nat. Cancer"},{"key":"3057_CR50","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.cell.2017.06.010","volume":"170","author":"A Tsherniak","year":"2017","unstructured":"Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564\u2013576.e16 (2017).","journal-title":"Cell"},{"key":"3057_CR51","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.trecan.2019.12.010","volume":"6","author":"S Garc\u00eda-Alonso","year":"2020","unstructured":"Garc\u00eda-Alonso, S., Oca\u00f1a, A. & Pandiella, A. Trastuzumab emtansine: mechanisms of action and resistance, clinical progress, and beyond. Trends Cancer 6, 130\u2013146 (2020).","journal-title":"Trends Cancer"},{"key":"3057_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-020-1252-7","volume":"22","author":"A Oca\u00f1a","year":"2020","unstructured":"Oca\u00f1a, A., Amir, E. & Pandiella, A. HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates. Breast Cancer Res. 22, 15 (2020).","journal-title":"Breast Cancer Res"},{"key":"3057_CR53","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.3390\/cancers12113271","volume":"12","author":"M Baliu-Piqu\u00e9","year":"2020","unstructured":"Baliu-Piqu\u00e9, M., Pandiella, A. & Ocana, A. Breast cancer heterogeneity and response to novel therapeutics. Cancers 12, 3271 (2020).","journal-title":"Cancers"},{"key":"3057_CR54","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/nmeth.3734","volume":"13","author":"J Fan","year":"2016","unstructured":"Fan, J. et al. Characterizing transcriptional heterogeneity through pathway and gene set overdispersion analysis. Nat. Methods 13, 241\u2013244 (2016).","journal-title":"Nat. Methods"},{"key":"3057_CR55","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s42003-023-04764-8","volume":"6","author":"E Revkov","year":"2023","unstructured":"Revkov, E., Kulshrestha, T., Sung, K. W.-K. & Skanderup, A. J. PUREE: accurate pan-cancer tumor purity estimation from gene expression data. Commun. Biol. 6, 394 (2023).","journal-title":"Commun. Biol."},{"key":"3057_CR56","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10628","volume":"9","author":"CP Tostado","year":"2024","unstructured":"Tostado, C. P. et al. An AI-assisted integrated, scalable, single-cell phenomic-transcriptomic platform to elucidate intratumor heterogeneity against immune response. Bioeng. Transl. Med. 9, e10628 (2024).","journal-title":"Bioeng. Transl. Med."},{"key":"3057_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101313","volume":"4","author":"M Dawood","year":"2023","unstructured":"Dawood, M. et al. Cross-linking breast tumor transcriptomic states and tissue histology. Cell Rep. Med. 4, 101313 (2023).","journal-title":"Cell Rep. Med."},{"key":"3057_CR58","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.ccell.2021.11.005","volume":"39","author":"CA Lareau","year":"2021","unstructured":"Lareau, C. A., Parker, K. R. & Satpathy, A. T. Charting the tumor antigen maps drawn by single-cell genomics. Cancer Cell 39, 1553\u20131557 (2021).","journal-title":"Cancer Cell"},{"key":"3057_CR59","doi-asserted-by":"crossref","unstructured":"Nix, M. A., Lareau, C. A., Verboon, J. & Kugler, D. G. Identifying optimal tumor-associated antigen combinations with single-cell genomics to enable multi-targeting therapies. Front. Immunol. 15, (2024).","DOI":"10.3389\/fimmu.2024.1492782"},{"key":"3057_CR60","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ccell.2025.03.017","volume":"43","author":"D Ma","year":"2025","unstructured":"Ma, D. et al. Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer. Cancer Cell 43, 1061\u20131075.e7 (2025).","journal-title":"Cancer Cell"},{"key":"3057_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-023-00491-9","volume":"8","author":"M Dawood","year":"2024","unstructured":"Dawood, M. et al. Cancer drug sensitivity prediction from routine histology images. NPJ Precis. Oncol. 8, 5 (2024).","journal-title":"NPJ Precis. Oncol."},{"key":"3057_CR62","doi-asserted-by":"crossref","unstructured":"Cheng, Y.-C. et al. PROFET predicts continuous gene expression dynamics from scRNA-seq data to elucidate heterogeneity of cancer treatment responses. Cell Syst. 101710 (2026).","DOI":"10.1016\/j.cels.2026.101710"},{"key":"3057_CR63","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1158\/2159-8290.CD-25-0647","volume":"16","author":"W Chen","year":"2026","unstructured":"Chen, W. et al. Trastuzumab deruxtecan resistance via loss of HER2 expression and binding. Cancer Discov. 16, 235\u2013249 (2026).","journal-title":"Cancer Discov."},{"key":"3057_CR64","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583\u2013589 (2021).","journal-title":"Nature"},{"key":"3057_CR65","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/978-1-0716-4007-4_12","volume":"2836","author":"A \u0160pa\u010dkov\u00e1","year":"2024","unstructured":"\u0160pa\u010dkov\u00e1, A. et al. Analysis and visualization of protein channels, tunnels, and pores with MOLEonline and channelsDB 2.0. Methods Mol. Biol. 2836, 219\u2013233 (2024).","journal-title":"Methods Mol. Biol."},{"key":"3057_CR66","doi-asserted-by":"publisher","first-page":"W431","DOI":"10.1093\/nar\/gkab314","volume":"49","author":"D Sehnal","year":"2021","unstructured":"Sehnal, D. et al. Mol* Viewer: modern web app for 3D visualization and analysis of large biomolecular structures. Nucleic Acids Res. 49, W431\u2013W437 (2021).","journal-title":"Nucleic Acids Res."},{"key":"3057_CR67","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baae012","volume":"2024","author":"J Wei","year":"2024","unstructured":"Wei, J. et al. ProNet DB: a proteome-wise database for protein surface property representations and RNA-binding profiles. Database 2024, baae012 (2024).","journal-title":"Database"},{"key":"3057_CR68","doi-asserted-by":"publisher","first-page":"9182","DOI":"10.1039\/D2CS00446A","volume":"51","author":"N Ashman","year":"2022","unstructured":"Ashman, N., Bargh, J. D. & Spring, D. R. Non-internalising antibody-drug conjugates. Chem. Soc. Rev. 51, 9182\u20139202 (2022).","journal-title":"Chem. Soc. Rev."},{"key":"3057_CR69","first-page":"15","volume":"12","author":"JES de Souza","year":"2012","unstructured":"de Souza, J. E. S. et al. SurfaceomeDB: a cancer-orientated database for genes encoding cell surface proteins. Cancer Immun. 12, 15 (2012).","journal-title":"Cancer Immun."},{"key":"3057_CR70","doi-asserted-by":"publisher","first-page":"E10988","DOI":"10.1073\/pnas.1808790115","volume":"115","author":"D Bausch-Fluck","year":"2018","unstructured":"Bausch-Fluck, D. et al. The in silico human surfaceome. Proc. Natl. Acad. Sci. USA. 115, E10988\u2013E10997 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3057_CR71","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1002\/prot.26648","volume":"92","author":"Z Su","year":"2024","unstructured":"Su, Z., Griffin, B., Emmons, S. & Wu, Y. Prediction of interactions between cell surface proteins by machine learning. Proteins 92, 567\u2013580 (2024).","journal-title":"Proteins"},{"key":"3057_CR72","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1146\/annurev.biochem.78.081307.110540","volume":"78","author":"GJ Doherty","year":"2009","unstructured":"Doherty, G. J. & McMahon, H. T. Mechanisms of endocytosis. Annu. Rev. Biochem. 78, 857\u2013902 (2009).","journal-title":"Annu. Rev. Biochem."},{"key":"3057_CR73","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8","volume":"16","author":"L-C Tsao","year":"2025","unstructured":"Tsao, L.-C. et al. Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd). Nat. Commun. 16, 3167 (2025).","journal-title":"Nat. Commun."},{"key":"3057_CR74","unstructured":"Llombart, P., Nieto-Jimenez, C., Pandiella, A. & Ocana, A. Computational mapping of antibody-receptor energy landscapes to predict internalization."},{"key":"3057_CR75","doi-asserted-by":"publisher","first-page":"a016949","DOI":"10.1101\/cshperspect.a016949","volume":"5","author":"I Mellman","year":"2013","unstructured":"Mellman, I. & Yarden, Y. Endocytosis and cancer. Cold Spring Harb. Perspect. Biol. 5, a016949 (2013).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"3057_CR76","doi-asserted-by":"publisher","first-page":"6570","DOI":"10.1158\/1078-0432.CCR-18-1300","volume":"24","author":"K Kinneer","year":"2018","unstructured":"Kinneer, K. et al. SLC46A3 as a potential predictive biomarker for antibody-drug conjugates bearing noncleavable linked maytansinoid and pyrrolobenzodiazepine warheads. Clin. Cancer Res. 24, 6570\u20136582 (2018).","journal-title":"Clin. Cancer Res."},{"key":"3057_CR77","doi-asserted-by":"publisher","DOI":"10.1093\/pnasnexus\/pgac063","volume":"1","author":"R Tomabechi","year":"2022","unstructured":"Tomabechi, R. et al. SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1. PNAS Nexus 1, pgac063 (2022).","journal-title":"PNAS Nexus"},{"key":"3057_CR78","doi-asserted-by":"publisher","first-page":"4639","DOI":"10.1158\/0008-5472.CAN-16-3127","volume":"77","author":"C R\u00edos-Luci","year":"2017","unstructured":"R\u00edos-Luci, C. et al. Resistance to the antibody-drug conjugate T-DM1 is based in a reduction in lysosomal proteolytic activity. Cancer Res 77, 4639\u20134651 (2017).","journal-title":"Cancer Res"},{"key":"3057_CR79","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3390\/cancers14010154","volume":"14","author":"E D\u00edaz-Rodr\u00edguez","year":"2021","unstructured":"D\u00edaz-Rodr\u00edguez, E., Gandullo-S\u00e1nchez, L., Oca\u00f1a, A. & Pandiella, A. Novel ADCs and strategies to overcome resistance to Anti-HER2 ADCs. Cancers 14, 154 (2021).","journal-title":"Cancers"},{"key":"3057_CR80","doi-asserted-by":"publisher","first-page":"1716","DOI":"10.3389\/fimmu.2018.01716","volume":"9","author":"D Gfeller","year":"2018","unstructured":"Gfeller, D. & Bassani-Sternberg, M. Predicting antigen presentation-what could we learn from a million peptides? Front. Immunol. 9, 1716 (2018).","journal-title":"Front. Immunol."},{"key":"3057_CR81","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1158\/2326-6066.CIR-19-0401","volume":"8","author":"J Hundal","year":"2020","unstructured":"Hundal, J. et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer Immunol. Res. 8, 409\u2013420 (2020).","journal-title":"Cancer Immunol. Res."},{"key":"3057_CR82","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gkaa379","volume":"48","author":"B Reynisson","year":"2020","unstructured":"Reynisson, B., Alvarez, B., Paul, S., Peters, B. & Nielsen, M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data. Nucleic Acids Res. 48, W449\u2013W454 (2020).","journal-title":"Nucleic Acids Res."},{"key":"3057_CR83","doi-asserted-by":"publisher","first-page":"1661","DOI":"10.1038\/s42003-024-07292-1","volume":"7","author":"DF Marzella","year":"2024","unstructured":"Marzella, D. F. et al. Geometric deep learning improves generalizability of MHC-bound peptide predictions. Commun. Biol. 7, 1661 (2024).","journal-title":"Commun. Biol."},{"key":"3057_CR84","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-53296-0","volume":"15","author":"H Xu","year":"2024","unstructured":"Xu, H. et al. ImmuneApp for HLA-I epitope prediction and immunopeptidome analysis. Nat. Commun. 15, 8926 (2024).","journal-title":"Nat. Commun."},{"key":"3057_CR85","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","volume":"8","author":"N Xie","year":"2023","unstructured":"Xie, N. et al. Neoantigens: promising targets for cancer therapy. Signal Transduct. Target Ther. 8, 9 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"3057_CR86","unstructured":"Acquisition of Neogene Therapeutics completed. https:\/\/www.astrazeneca.com\/media-centre\/press-releases\/2023\/acquisition-of-neogene-therapeutics-completed.html (2023)."},{"key":"3057_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-36028-8","volume":"14","author":"J Parkinson","year":"2023","unstructured":"Parkinson, J., Hard, R. & Wang, W. The RESP AI model accelerates the identification of tight-binding antibodies. Nat. Commun. 14, 454 (2023).","journal-title":"Nat. Commun."},{"key":"3057_CR88","doi-asserted-by":"publisher","unstructured":"Greenig, M., Zhao, H., Radenkovic, V., Ramon, A., Sormanni, P. IgCraft: A versatile sequence generation framework for antibody discovery and engineering. Preprint at: https:\/\/doi.org\/10.48550\/arXiv.2503.19821.","DOI":"10.48550\/arXiv.2503.19821"},{"key":"3057_CR89","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/s41586-025-09721-5","volume":"649","author":"NR Bennett","year":"2026","unstructured":"Bennett, N. R. et al. Atomically accurate de novo design of antibodies with RFdiffusion. Nature 649, 183\u2013193 (2026).","journal-title":"Nature"},{"key":"3057_CR90","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-31457-3","volume":"13","author":"EK Makowski","year":"2022","unstructured":"Makowski, E. K. et al. Co-optimization of therapeutic antibody affinity and specificity using machine learning models that generalize to novel mutational space. Nat. Commun. 13, 3788 (2022).","journal-title":"Nat. Commun."},{"key":"3057_CR91","doi-asserted-by":"publisher","first-page":"11543","DOI":"10.1021\/acs.jcim.5c01577","volume":"65","author":"K Furui","year":"2025","unstructured":"Furui, K. & Ohue, M. ALLM-Ab: active learning-driven antibody optimization using fine-tuned protein language models. J. Chem. Inf. Model 65, 11543\u201311557 (2025).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR92","doi-asserted-by":"publisher","unstructured":"Gao, J. et al. Precise antigen-antibody structure predictions enhance antibody development with helixfold-multimer. Preprint at https:\/\/doi.org\/10.48550\/arXiv.2412.09826 (2024).","DOI":"10.48550\/arXiv.2412.09826"},{"key":"3057_CR93","doi-asserted-by":"crossref","unstructured":"Dreyer, F. A. et al. Conformation-aware structure prediction of antigen-recognizing immune proteins. MAbs 18, 2602217.","DOI":"10.1080\/19420862.2025.2602217"},{"key":"3057_CR94","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbaf445","volume":"26","author":"J Li","year":"2025","unstructured":"Li, J. et al. Significantly enhancing human antibody affinity via deep learning and computational biology-guided single-point mutations. Brief. Bioinform. 26, bbaf445 (2025).","journal-title":"Brief. Bioinform."},{"key":"3057_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-01159-2","volume":"9","author":"Y Lu","year":"2025","unstructured":"Lu, Y. et al. Leveraging artificial intelligence in antibody-drug conjugate development: from target identification to clinical translation in oncology. NPJ Precis. Oncol. 9, 374 (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"3057_CR96","doi-asserted-by":"publisher","unstructured":"Zhou, Y. et al. AI-guided design of common light chains to enable manufacturable bispecific antibodies. Preprint at https:\/\/doi.org\/10.1101\/2025.10.11.681265 (2025).","DOI":"10.1101\/2025.10.11.681265"},{"key":"3057_CR97","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2175319","volume":"15","author":"ML Fern\u00e1ndez-Quintero","year":"2023","unstructured":"Fern\u00e1ndez-Quintero, M. L. et al. Challenges in antibody structure prediction. MAbs 15, 2175319 (2023).","journal-title":"MAbs"},{"key":"3057_CR98","doi-asserted-by":"publisher","first-page":"e4865","DOI":"10.1002\/pro.4865","volume":"33","author":"R Yin","year":"2024","unstructured":"Yin, R. & Pierce, B. G. Evaluation of AlphaFold antibody-antigen modeling with implications for improving predictive accuracy. Protein Sci. 33, e4865 (2024).","journal-title":"Protein Sci."},{"key":"3057_CR99","doi-asserted-by":"publisher","first-page":"2545601","DOI":"10.1080\/19420862.2025.2545601","volume":"17","author":"FN Hitawala","year":"2025","unstructured":"Hitawala, F. N. & Gray, J. J. What does AlphaFold3 learn about antibody and nanobody docking, and what remains unsolved? MAbs 17, 2545601 (2025).","journal-title":"MAbs"},{"key":"3057_CR100","doi-asserted-by":"publisher","first-page":"vbaf161","DOI":"10.1093\/bioadv\/vbaf161","volume":"5","author":"X Xu","year":"2025","unstructured":"Xu, X., Giulini, M. & Bonvin, A. M. J. J. Improved prediction of antibody and their complexes with clustered generative modelling ensembles. Bioinform Adv. 5, vbaf161 (2025).","journal-title":"Bioinform Adv."},{"key":"3057_CR101","doi-asserted-by":"publisher","first-page":"lqag002","DOI":"10.1093\/nargab\/lqag002","volume":"8","author":"SK Mahtha","year":"2026","unstructured":"Mahtha, S. K., Venkadesan, S. & Mohanty, D. Comparative evaluation of the prediction accuracy of AlphaFold and ESMFold for monomeric and dimeric proteins. NAR Genom. Bioinform 8, lqag002 (2026).","journal-title":"NAR Genom. Bioinform"},{"key":"3057_CR102","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1080\/19420862.2019.1618676","volume":"11","author":"ML Fern\u00e1ndez-Quintero","year":"2019","unstructured":"Fern\u00e1ndez-Quintero, M. L., Kraml, J., Georges, G. & Liedl, K. R. CDR-H3 loop ensemble in solution - conformational selection upon antibody binding. MAbs 11, 1077\u20131088 (2019).","journal-title":"MAbs"},{"key":"3057_CR103","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.3390\/life11121428","volume":"11","author":"R Higashida","year":"2021","unstructured":"Higashida, R. & Matsunaga, Y. Enhanced conformational sampling of nanobody CDR H3 loop by generalized replica-exchange with solute tempering. Life 11, 1428 (2021).","journal-title":"Life"},{"key":"3057_CR104","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2171248","volume":"15","author":"ML Fern\u00e1ndez-Quintero","year":"2023","unstructured":"Fern\u00e1ndez-Quintero, M. L. et al. Assessing developability early in the discovery process for novel biologics. MAbs 15, 2171248 (2023).","journal-title":"MAbs"},{"key":"3057_CR105","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2474521","volume":"17","author":"B Li","year":"2025","unstructured":"Li, B. et al. PROPERMAB: an integrative framework for in silico prediction of antibody developability using machine learning. MAbs 17, 2474521 (2025).","journal-title":"MAbs"},{"key":"3057_CR106","doi-asserted-by":"publisher","first-page":"4025","DOI":"10.1073\/pnas.1810576116","volume":"116","author":"MIJ Raybould","year":"2019","unstructured":"Raybould, M. I. J. et al. Five computational developability guidelines for therapeutic antibody profiling. Proc. Natl. Acad. Sci. USA. 116, 4025\u20134030 (2019).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3057_CR107","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","volume":"46","author":"CA Lipinski","year":"2001","unstructured":"Lipinski, C. A., Lombardo, F., Dominy, B. W. & Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46, 3\u201326 (2001).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3057_CR108","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2362775","volume":"16","author":"M Hutchinson","year":"2024","unstructured":"Hutchinson, M. et al. Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen. MAbs 16, 2362775 (2024).","journal-title":"MAbs"},{"key":"3057_CR109","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00764-4","volume":"13","author":"V Dewaker","year":"2025","unstructured":"Dewaker, V. et al. Revolutionizing oncology: the role of Artificial Intelligence (AI) as an antibody design, and optimization tools. Biomark. Res. 13, 52 (2025).","journal-title":"Biomark. Res."},{"key":"3057_CR110","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adz8759","volume":"11","author":"J Kim","year":"2025","unstructured":"Kim, J. et al. T-SCAPE: T cell immunogenicity scoring via cross-domain aided predictive engine. Sci. Adv. 11, eadz8759 (2025).","journal-title":"Sci. Adv."},{"key":"3057_CR111","doi-asserted-by":"publisher","unstructured":"Chungyoun, M. & Gray, J. Fitness landscape for antibodies 2: Benchmarking reveals that protein AI models cannot yet consistently predict developability properties. 2025.12.27.696706 Preprint at https:\/\/doi.org\/10.64898\/2025.12.27.696706 (2025).","DOI":"10.64898\/2025.12.27.696706"},{"key":"3057_CR112","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1016\/j.apsb.2021.03.042","volume":"11","author":"Z Su","year":"2021","unstructured":"Su, Z. et al. Antibody-drug conjugates: recent advances in linker chemistry. Acta Pharm. Sin. B. 11, 3889\u20133907 (2021).","journal-title":"Acta Pharm. Sin. B"},{"key":"3057_CR113","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4161\/mabs.27022","volume":"6","author":"S Panowski","year":"2014","unstructured":"Panowski, S., Bhakta, S., Raab, H., Polakis, P. & Junutula, J. R. Site-specific antibody drug conjugates for cancer therapy. MAbs 6, 34\u201345 (2014).","journal-title":"MAbs"},{"key":"3057_CR114","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/nbt.1480","volume":"26","author":"JR Junutula","year":"2008","unstructured":"Junutula, J. R. et al. Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index. Nat. Biotechnol. 26, 925\u2013932 (2008).","journal-title":"Nat. Biotechnol."},{"key":"3057_CR115","doi-asserted-by":"publisher","first-page":"16101","DOI":"10.1073\/pnas.1211023109","volume":"109","author":"JY Axup","year":"2012","unstructured":"Axup, J. Y. et al. Synthesis of site-specific antibody-drug conjugates using unnatural amino acids. Proc. Natl. Acad. Sci. USA 109, 16101\u201316106 (2012).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3057_CR116","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/nbt.3274","volume":"33","author":"P Strop","year":"2015","unstructured":"Strop, P. et al. Site-specific conjugation improves therapeutic index of antibody drug conjugates with high drug loading. Nat. Biotechnol. 33, 694\u2013696 (2015).","journal-title":"Nat. Biotechnol."},{"key":"3057_CR117","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1021\/acs.bioconjchem.7b00791","volume":"29","author":"R Ohri","year":"2018","unstructured":"Ohri, R. et al. High-throughput cysteine scanning to identify stable antibody conjugation sites for maleimide- and disulfide-based linkers. Bioconjug Chem. 29, 473\u2013485 (2018).","journal-title":"Bioconjug Chem."},{"key":"3057_CR118","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1021\/acs.jmedchem.2c01812","volume":"66","author":"W Shi","year":"2023","unstructured":"Shi, W. et al. Hiding payload inside the IgG Fc cavity significantly enhances the therapeutic index of antibody-drug conjugates. J. Med. Chem. 66, 1011\u20131026 (2023).","journal-title":"J. Med. Chem."},{"key":"3057_CR119","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3390\/antib12040071","volume":"12","author":"Q Yang","year":"2023","unstructured":"Yang, Q. et al. Evaluation of two chemoenzymatic glycan remodeling approaches to generate site-specific antibody-drug conjugates. Antibodies 12, 71 (2023).","journal-title":"Antibodies"},{"key":"3057_CR120","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1039\/D5CB00096C","volume":"6","author":"Q Xue","year":"2025","unstructured":"Xue, Q. et al. A biparatopic HER2-targeting ADC constructed via site-specific glycan conjugation exhibits superior stability, safety, and efficacy. RSC Chem. Biol. 6, 1284\u20131296 (2025).","journal-title":"RSC Chem. Biol."},{"key":"3057_CR121","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/nprot.2016.180","volume":"12","author":"BD Weitzner","year":"2017","unstructured":"Weitzner, B. D. et al. Modeling and docking of antibody structures with Rosetta. Nat. Protoc. 12, 401\u2013416 (2017).","journal-title":"Nat. Protoc."},{"key":"3057_CR122","unstructured":"Ingraham, J., Garg, V., Barzilay, R. & Jaakkola, T. Generative models for graph-based protein design. In Advances in Neural Information Processing Systems vol. 32 (Curran Associates, Inc., 2019)."},{"key":"3057_CR123","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2016239118","volume":"118","author":"A Rives","year":"2021","unstructured":"Rives, A. et al. Biological structure and function emerge from scaling unsupervised learning to 250 million protein sequences. Proc. Natl. Acad. Sci. USA 118, e2016239118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"3057_CR124","doi-asserted-by":"publisher","first-page":"e254","DOI":"10.1016\/S1470-2045(16)30030-4","volume":"17","author":"A Thomas","year":"2016","unstructured":"Thomas, A., Teicher, B. A. & Hassan, R. Antibody-drug conjugates for cancer therapy. Lancet Oncol. 17, e254\u2013e262 (2016).","journal-title":"Lancet Oncol."},{"key":"3057_CR125","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nbt.3212","volume":"33","author":"RP Lyon","year":"2015","unstructured":"Lyon, R. P. et al. Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index. Nat. Biotechnol. 33, 733\u2013735 (2015).","journal-title":"Nat. Biotechnol."},{"key":"3057_CR126","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","volume":"36","author":"J Long","year":"2025","unstructured":"Long, J. et al. PEGylation of dipeptide linker improves therapeutic index and pharmacokinetics of antibody-drug conjugates. Bioconjug. Chem. 36, 179\u2013189 (2025).","journal-title":"Bioconjug. Chem."},{"key":"3057_CR127","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1038\/s41589-025-01950-z","volume":"21","author":"A Croitoru","year":"2025","unstructured":"Croitoru, A., Orr, A. A. & MacKerell, A. D. Harnessing computational technologies to facilitate antibody-drug conjugate development. Nat. Chem. Biol. 21, 1138\u20131147 (2025).","journal-title":"Nat. Chem. Biol."},{"key":"3057_CR128","doi-asserted-by":"publisher","unstructured":"Lam, I. et al. Quantitative systems pharmacology modeling of pyrrolobenzodiazepine antibody-drug conjugates targeting BCMA. Preprint at https:\/\/doi.org\/10.1101\/2025.02.20.639376 (2025).","DOI":"10.1101\/2025.02.20.639376"},{"key":"3057_CR129","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1002\/psp4.70071","volume":"14","author":"C Zunino","year":"2025","unstructured":"Zunino, C. et al. Prediction of a CLDN18.2 targeted antibody drug conjugate pharmacokinetics in cancer patients using PBPK modeling and simulation. CPT Pharmacomet. Syst. Pharm. 14, 1494\u20131503 (2025).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"3057_CR130","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s13046-017-0667-1","volume":"37","author":"C Chalouni","year":"2018","unstructured":"Chalouni, C. & Doll, S. Fate of antibody-drug conjugates in cancer cells. J. Exp. Clin. Cancer Res. 37, 20 (2018).","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"3057_CR131","doi-asserted-by":"publisher","first-page":"13","DOI":"10.4161\/mabs.22854","volume":"5","author":"M Ritchie","year":"2013","unstructured":"Ritchie, M., Tchistiakova, L. & Scott, N. Implications of receptor-mediated endocytosis and intracellular trafficking dynamics in the development of antibody drug conjugates. MAbs 5, 13\u201321 (2013).","journal-title":"MAbs"},{"key":"3057_CR132","doi-asserted-by":"publisher","first-page":"4361","DOI":"10.1039\/C8CS00676H","volume":"48","author":"JD Bargh","year":"2019","unstructured":"Bargh, J. D., Isidro-Llobet, A., Parker, J. S. & Spring, D. R. Cleavable linkers in antibody-drug conjugates. Chem. Soc. Rev. 48, 4361\u20134374 (2019).","journal-title":"Chem. Soc. Rev."},{"key":"3057_CR133","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1021\/bc9002019","volume":"21","author":"L Ducry","year":"2010","unstructured":"Ducry, L. & Stump, B. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug. Chem. 21, 5\u201313 (2010).","journal-title":"Bioconjug. Chem."},{"key":"3057_CR134","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-05555-3","volume":"15","author":"A Su","year":"2025","unstructured":"Su, A., Luo, Y., Zhang, C. & Duan, H. Linker-GPT: design of antibody-drug conjugates linkers with molecular generators and reinforcement learning. Sci. Rep. 15, 20525 (2025).","journal-title":"Sci. Rep."},{"key":"3057_CR135","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/ph17101338","volume":"17","author":"B Valsasina","year":"2024","unstructured":"Valsasina, B., Orsini, P., Terenghi, C. & Ocana, A. Present scenario and future landscape of payloads for ADCs: focus on DNA-interacting agents. Pharmaceuticals 17, 1338 (2024).","journal-title":"Pharmaceuticals"},{"key":"3057_CR136","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","volume":"7","author":"Z Fu","year":"2022","unstructured":"Fu, Z., Li, S., Han, S., Shi, C. & Zhang, Y. Antibody drug conjugate: the \u2018biological missile\u2019 for targeted cancer therapy. Signal Transduct. Target Ther. 7, 93 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"3057_CR137","doi-asserted-by":"publisher","DOI":"10.1186\/s40364-025-00758-2","volume":"13","author":"A Ocana","year":"2025","unstructured":"Ocana, A. et al. Integrating artificial intelligence in drug discovery and early drug development: a transformative approach. Biomark. Res. 13, 45 (2025).","journal-title":"Biomark. Res."},{"key":"3057_CR138","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241309461","volume":"17","author":"D Izzo","year":"2025","unstructured":"Izzo, D. et al. Innovative payloads for ADCs in cancer treatment: moving beyond the selective delivery of chemotherapy. Ther. Adv. Med. Oncol. 17, 17588359241309461 (2025).","journal-title":"Ther. Adv. Med. Oncol."},{"key":"3057_CR139","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1182\/blood-2024-201221","volume":"144","author":"X Dong","year":"2024","unstructured":"Dong, X. et al. Potent in vitro and in vivo efficacy of Hdz-C123A, a GSPT1 degrader-antibody conjugate targeting CD123 in acute myeloid leukemia. Blood 144, 156\u2013156 (2024).","journal-title":"Blood"},{"key":"3057_CR140","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1158\/1535-7163.MCT-20-0618","volume":"20","author":"PN Moquist","year":"2021","unstructured":"Moquist, P. N. et al. Novel auristatins with high bystander and cytotoxic activities in drug efflux-positive tumor models. Mol. Cancer Ther. 20, 320\u2013328 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"3057_CR141","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-med-061516-121357","volume":"69","author":"JM Lambert","year":"2018","unstructured":"Lambert, J. M. & Berkenblit, A. Antibody-drug conjugates for cancer treatment. Annu. Rev. Med. 69, 191\u2013207 (2018).","journal-title":"Annu. Rev. Med."},{"key":"3057_CR142","doi-asserted-by":"publisher","first-page":"15996","DOI":"10.1021\/acs.jmedchem.4c01289","volume":"67","author":"YB Poudel","year":"2024","unstructured":"Poudel, Y. B., Thakore, R. R. & Chekler, E. P. The new frontier: merging molecular glue degrader and antibody-drug conjugate modalities to overcome strategic challenges. J. Med. Chem. 67, 15996\u201316001 (2024).","journal-title":"J. Med. Chem."},{"key":"3057_CR143","doi-asserted-by":"publisher","DOI":"10.1002\/cmdc.202500262","volume":"20","author":"Y Lei","year":"2025","unstructured":"Lei, Y. et al. Linker Design for the antibody drug conjugates: a comprehensive review. ChemMedChem 20, e202500262 (2025).","journal-title":"ChemMedChem"},{"key":"3057_CR144","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1080\/19420862.2019.1632115","volume":"11","author":"DM Goldenberg","year":"2019","unstructured":"Goldenberg, D. M. & Sharkey, R. M. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: a case study of anti-TROP-2 sacituzumab govitecan. MAbs 11, 987\u2013995 (2019).","journal-title":"MAbs"},{"key":"3057_CR145","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-13810-w","volume":"15","author":"VL Cruz","year":"2025","unstructured":"Cruz, V. L. et al. In silico decrypting of the bystander effect in antibody-drug conjugates for breast cancer therapy. Sci. Rep. 15, 28715 (2025).","journal-title":"Sci. Rep."},{"key":"3057_CR146","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202306309","volume":"11","author":"Y Guo","year":"2024","unstructured":"Guo, Y. et al. Rational identification of novel antibody-drug conjugate with high bystander killing effect against heterogeneous tumors. Adv. Sci. 11, e2306309 (2024).","journal-title":"Adv. Sci."},{"key":"3057_CR147","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1038\/d41573-025-00121-y","volume":"24","author":"A Mullard","year":"2025","unstructured":"Mullard, A. Dual-payload ADCs move into first oncology clinical trials. Nat. Rev. Drug Discov. 24, 573\u2013576 (2025).","journal-title":"Nat. Rev. Drug Discov."},{"key":"3057_CR148","doi-asserted-by":"publisher","first-page":"116995","DOI":"10.1016\/j.ejmech.2024.116995","volume":"281","author":"J Tao","year":"2025","unstructured":"Tao, J., Gu, Y., Zhou, W. & Wang, Y. Dual-payload antibody-drug conjugates: taking a dual shot. Eur. J. Med. Chem. 281, 116995 (2025).","journal-title":"Eur. J. Med. Chem."},{"key":"3057_CR149","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-23793-7","volume":"12","author":"CM Yamazaki","year":"2021","unstructured":"Yamazaki, C. M. et al. Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance. Nat. Commun. 12, 3528 (2021).","journal-title":"Nat. Commun."},{"key":"3057_CR150","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1158\/1538-7445.AM2025-1586","volume":"85","author":"Y Zhao","year":"2025","unstructured":"Zhao, Y. et al. Abstract 1586: KH815, a novel dual-payload TROP2-directed antibody-drug conjugate, shows potent antitumor efficacy in pre-clinical tumor model. Cancer Res. 85, 1586 (2025).","journal-title":"Cancer Res."},{"key":"3057_CR151","unstructured":"Biologics, I. Innovent announces first patient dosed in phase 1 Study of IBI3020, global first-in-class dual payload CEACAM5 ADC, in patients with advanced malignancies. https:\/\/www.prnewswire.com\/news-releases\/innovent-announces-first-patient-dosed-in-phase-1-study-of-ibi3020-global-first-in-class-dual-payload-ceacam5-adc--in-patients-with-advanced-malignancies-302441146.html."},{"key":"3057_CR152","doi-asserted-by":"publisher","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","volume":"17","author":"M Wen","year":"2025","unstructured":"Wen, M. et al. Homogeneous antibody-drug conjugates with dual payloads: potential, methods and considerations. MAbs 17, 2498162 (2025).","journal-title":"MAbs"},{"key":"3057_CR153","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s41746-025-01435-2","volume":"8","author":"J Chen","year":"2025","unstructured":"Chen, J. et al. Computational frameworks transform antagonism to synergy in optimizing combination therapies. NPJ Digit. Med. 8, 44 (2025).","journal-title":"NPJ Digit. Med."},{"key":"3057_CR154","doi-asserted-by":"publisher","first-page":"4859","DOI":"10.3390\/ijms26104859","volume":"26","author":"S Xu","year":"2025","unstructured":"Xu, S., Xie, L., Dai, R., Lyu, Z. & Dumpling, G. N. N. Hybrid GNN enables better ADC payload activity prediction based on the chemical structure. Int. J. Mol. Sci. 26, 4859 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"3057_CR155","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-12830-5","volume":"7","author":"HS Lee","year":"2017","unstructured":"Lee, H. S. & Im, W. Effects of N-glycan composition on structure and dynamics of IgG1 Fc and their implications for antibody engineering. Sci. Rep. 7, 12659 (2017).","journal-title":"Sci. Rep."},{"key":"3057_CR156","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/978-1-0716-2609-2_6","volume":"2552","author":"A Tucs","year":"2023","unstructured":"Tucs, A., Tsuda, K. & Sljoka, A. Probing conformational dynamics of antibodies with geometric simulations. Methods Mol. Biol. 2552, 125\u2013139 (2023).","journal-title":"Methods Mol. Biol."},{"key":"3057_CR157","doi-asserted-by":"publisher","first-page":"7828","DOI":"10.1021\/jacs.1c03174","volume":"143","author":"C Li","year":"2021","unstructured":"Li, C. et al. Site-selective chemoenzymatic modification on the core fucose of an antibody enhances its Fc\u03b3 receptor affinity and ADCC activity. J. Am. Chem. Soc. 143, 7828\u20137838 (2021).","journal-title":"J. Am. Chem. Soc."},{"key":"3057_CR158","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1002\/bit.26244","volume":"114","author":"VG Poosarla","year":"2017","unstructured":"Poosarla, V. G. et al. Computational de novo design of antibodies binding to a peptide with high affinity. Biotechnol. Bioeng. 114, 1331\u20131342 (2017).","journal-title":"Biotechnol. Bioeng."},{"key":"3057_CR159","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nmeth.4067","volume":"14","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. CHARMM36m: an improved force field for folded and intrinsically disordered proteins. Nat. Methods 14, 71\u201373 (2017).","journal-title":"Nat. Methods"},{"key":"3057_CR160","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1021\/acs.jctc.5b00356","volume":"11","author":"MJ Robertson","year":"2015","unstructured":"Robertson, M. J., Tirado-Rives, J. & Jorgensen, W. L. Improved peptide and protein torsional energetics with the OPLSAA force field. J. Chem. Theory Comput 11, 3499\u20133509 (2015).","journal-title":"J. Chem. Theory Comput"},{"key":"3057_CR161","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1021\/acs.jctc.9b00591","volume":"16","author":"C Tian","year":"2020","unstructured":"Tian, C. et al. ff19SB: amino-acid-specific protein backbone parameters trained against quantum mechanics energy surfaces in solution. J. Chem. Theory Comput. 16, 528\u2013552 (2020).","journal-title":"J. Chem. Theory Comput."},{"key":"3057_CR162","doi-asserted-by":"publisher","first-page":"118001","DOI":"10.1103\/PhysRevLett.130.118001","volume":"130","author":"I Sanchez-Burgos","year":"2023","unstructured":"Sanchez-Burgos, I. & Espinosa, J. R. Direct calculation of the interfacial free energy between NaCl crystal and its aqueous solution at the solubility limit. Phys. Rev. Lett. 130, 118001 (2023).","journal-title":"Phys. Rev. Lett."},{"key":"3057_CR163","doi-asserted-by":"publisher","DOI":"10.1063\/1.5001190","volume":"147","author":"AL Benavides","year":"2017","unstructured":"Benavides, A. L. et al. A potential model for sodium chloride solutions based on the TIP4P\/2005 water model. J. Chem. Phys. 147, 104501 (2017).","journal-title":"J. Chem. Phys."},{"key":"3057_CR164","doi-asserted-by":"publisher","first-page":"154102","DOI":"10.1063\/1.4801322","volume":"138","author":"F Mou\u010dka","year":"2013","unstructured":"Mou\u010dka, F., Nezbeda, I. & Smith, W. R. Molecular force fields for aqueous electrolytes: SPC\/E-compatible charged LJ sphere models and their limitations. J. Chem. Phys. 138, 154102 (2013).","journal-title":"J. Chem. Phys."},{"key":"3057_CR165","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1002\/jcc.21367","volume":"31","author":"K Vanommeslaeghe","year":"2010","unstructured":"Vanommeslaeghe, K. et al. CHARMM general force field: a force field for drug-like molecules compatible with the CHARMM all-atom additive biological force fields. J. Comput. Chem. 31, 671\u2013690 (2010).","journal-title":"J. Comput. Chem."},{"key":"3057_CR166","doi-asserted-by":"publisher","first-page":"4482","DOI":"10.1021\/acs.jctc.2c00015","volume":"18","author":"MJ Robertson","year":"2022","unstructured":"Robertson, M. J. & Skiniotis, G. Development of OPLS-AA\/M parameters for simulations of G protein-coupled receptors and other membrane proteins. J. Chem. Theory Comput 18, 4482\u20134489 (2022).","journal-title":"J. Chem. Theory Comput"},{"key":"3057_CR167","doi-asserted-by":"publisher","first-page":"W331","DOI":"10.1093\/nar\/gkx312","volume":"45","author":"LS Dodda","year":"2017","unstructured":"Dodda, L. S., Cabeza de Vaca, I., Tirado-Rives, J. & Jorgensen, W. L. LigParGen web server: an automatic OPLS-AA parameter generator for organic ligands. Nucleic Acids Res. 45, W331\u2013W336 (2017).","journal-title":"Nucleic Acids Res."},{"key":"3057_CR168","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1002\/jcc.20035","volume":"25","author":"J Wang","year":"2004","unstructured":"Wang, J., Wolf, R. M., Caldwell, J. W., Kollman, P. A. & Case, D. A. Development and testing of a general amber force field. J. Comput. Chem. 25, 1157\u20131174 (2004).","journal-title":"J. Comput. Chem."},{"key":"3057_CR169","first-page":"622","volume":"29","author":"KN Kirschner","year":"2008","unstructured":"Kirschner, K. N. et al. GLYCAM06: a generalizable biomolecular force field. Carbohydr. J. Comput. Chem. 29, 622\u2013655 (2008).","journal-title":"Carbohydr. J. Comput. Chem."},{"key":"3057_CR170","doi-asserted-by":"publisher","first-page":"5281","DOI":"10.1021\/acs.jpcb.4c00157","volume":"128","author":"J Miao","year":"2024","unstructured":"Miao, J. et al. Assessing the performance of peptide force fields for modeling the solution structural ensembles of cyclic peptides. J. Phys. Chem. B. 128, 5281\u20135292 (2024).","journal-title":"J. Phys. Chem. B"},{"key":"3057_CR171","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1021\/ct200328p","volume":"7","author":"O Guvench","year":"2011","unstructured":"Guvench, O. et al. CHARMM additive all-atom force field for carbohydrate derivatives and its utility in polysaccharide and carbohydrate-protein modeling. J. Chem. Theory Comput. 7, 3162\u20133180 (2011).","journal-title":"J. Chem. Theory Comput."},{"key":"3057_CR172","doi-asserted-by":"publisher","first-page":"2135","DOI":"10.1002\/jcc.23354","volume":"34","author":"J Huang","year":"2013","unstructured":"Huang, J. & MacKerell, A. D. CHARMM36 all-atom additive protein force field: validation based on comparison to NMR data. J. Comput. Chem. 34, 2135\u20132145 (2013).","journal-title":"J. Comput. Chem."},{"key":"3057_CR173","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1021\/acs.nanolett.1c03138","volume":"22","author":"TJ Welsh","year":"2022","unstructured":"Welsh, T. J. et al. Surface electrostatics govern the emulsion stability of biomolecular condensates. Nano Lett. 22, 612\u2013621 (2022).","journal-title":"Nano Lett."},{"key":"3057_CR174","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-64098-3","volume":"16","author":"K Borthakur","year":"2025","unstructured":"Borthakur, K., Sisk, T. R., Panei, F. P., Bonomi, M. & Robustelli, P. Determining accurate conformational ensembles of intrinsically disordered proteins at atomic resolution. Nat. Commun. 16, 9036 (2025).","journal-title":"Nat. Commun."},{"key":"3057_CR175","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1021\/acs.jcim.6c00083","volume":"66","author":"A Feito","year":"2026","unstructured":"Feito, A. et al. Comparative assessment of free energy computational methods for revealing the interactions driving PARP1 selective inhibition. J. Chem. Inf. Model 66, 5315\u20135330 (2026).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR176","doi-asserted-by":"publisher","first-page":"e5172","DOI":"10.1002\/pro.5172","volume":"33","author":"F Cao","year":"2024","unstructured":"Cao, F., von B\u00fclow, S., Tesei, G. & Lindorff-Larsen, K. A coarse-grained model for disordered and multi-domain proteins. Protein Sci. 33, e5172 (2024).","journal-title":"Protein Sci."},{"key":"3057_CR177","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/pro.4094","volume":"30","author":"RM Regy","year":"2021","unstructured":"Regy, R. M., Thompson, J., Kim, Y. C. & Mittal, J. Improved coarse-grained model for studying sequence dependent phase separation of disordered proteins. Protein Sci. 30, 1371\u20131379 (2021).","journal-title":"Protein Sci."},{"key":"3057_CR178","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1021\/acscentsci.4c01617","volume":"11","author":"A R Tejedor","year":"2025","unstructured":"R Tejedor, A. et al. Chemically informed coarse-graining of electrostatic forces in charge-rich biomolecular condensates. ACS Cent. Sci. 11, 302\u2013321 (2025).","journal-title":"ACS Cent. Sci."},{"key":"3057_CR179","doi-asserted-by":"publisher","first-page":"125103","DOI":"10.1063\/5.0062687","volume":"155","author":"A Garaizar","year":"2021","unstructured":"Garaizar, A. & Espinosa, J. R. Salt dependent phase behavior of intrinsically disordered proteins from a coarse-grained model with explicit water and ions. J. Chem. Phys. 155, 125103 (2021).","journal-title":"J. Chem. Phys."},{"key":"3057_CR180","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1021\/acs.jpcb.5b07260","volume":"120","author":"PD Godfrin","year":"2016","unstructured":"Godfrin, P. D. et al. Effect of hierarchical cluster formation on the viscosity of concentrated monoclonal antibody formulations studied by neutron scattering. J. Phys. Chem. B 120, 278\u2013291 (2016).","journal-title":"J. Phys. Chem. B"},{"key":"3057_CR181","doi-asserted-by":"publisher","first-page":"5274","DOI":"10.1021\/acs.jpcb.9b04478","volume":"123","author":"BJ Dear","year":"2019","unstructured":"Dear, B. J. et al. X-ray scattering and coarse-grained simulations for clustering and interactions of monoclonal antibodies at high concentrations. J. Phys. Chem. B 123, 5274\u20135290 (2019).","journal-title":"J. Phys. Chem. B"},{"key":"3057_CR182","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/s41592-021-01098-3","volume":"18","author":"PCT Souza","year":"2021","unstructured":"Souza, P. C. T. et al. Martini 3: a general purpose force field for coarse-grained molecular dynamics. Nat. Methods 18, 382\u2013388 (2021).","journal-title":"Nat. Methods"},{"key":"3057_CR183","unstructured":"Excessive aggregation of membrane proteins in the Martini model. https:\/\/pubmed.ncbi.nlm.nih.gov\/29131844\/."},{"key":"3057_CR184","doi-asserted-by":"publisher","first-page":"7749","DOI":"10.1021\/acs.jcim.4c01652","volume":"65","author":"H Ayaz","year":"2025","unstructured":"Ayaz, H. et al. Network-driven methods using gene expression signatures to find therapeutic targets in breast cancer validated via molecular dynamics studies. J. Chem. Inf. Model 65, 7749\u20137766 (2025).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR185","doi-asserted-by":"publisher","first-page":"4705","DOI":"10.3390\/molecules25204705","volume":"25","author":"A Garaizar","year":"2020","unstructured":"Garaizar, A., Sanchez-Burgos, I., Collepardo-Guevara, R. & Espinosa, J. R. Expansion of intrinsically disordered proteins increases the range of stability of liquid-liquid phase separation. Molecules 25, 4705 (2020).","journal-title":"Molecules"},{"key":"3057_CR186","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1021\/acs.jpcb.1c01903","volume":"125","author":"H Shahfar","year":"2021","unstructured":"Shahfar, H., Forder, J. K. & Roberts, C. J. Toward a suite of coarse-grained models for molecular simulation of monoclonal antibodies and therapeutic proteins. J. Phys. Chem. B 125, 3574\u20133588 (2021).","journal-title":"J. Phys. Chem. B"},{"key":"3057_CR187","doi-asserted-by":"publisher","first-page":"224510","DOI":"10.1063\/1.5098551","volume":"150","author":"JR Espinosa","year":"2019","unstructured":"Espinosa, J. R., Garaizar, A., Vega, C., Frenkel, D. & Collepardo-Guevara, R. Breakdown of the law of rectilinear diameter and related surprises in the liquid-vapor coexistence in systems of patchy particles. J. Chem. Phys. 150, 224510 (2019).","journal-title":"J. Chem. Phys."},{"key":"3057_CR188","doi-asserted-by":"publisher","first-page":"014504","DOI":"10.1063\/1.3153843","volume":"131","author":"J Russo","year":"2009","unstructured":"Russo, J., Tartaglia, P. & Sciortino, F. Reversible gels of patchy particles: role of the valence. J. Chem. Phys. 131, 014504 (2009).","journal-title":"J. Chem. Phys."},{"key":"3057_CR189","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-08130-2","volume":"12","author":"A Garaizar","year":"2022","unstructured":"Garaizar, A., Espinosa, J. R., Joseph, J. A. & Collepardo-Guevara, R. Kinetic interplay between droplet maturation and coalescence modulates shape of aged protein condensates. Sci. Rep. 12, 4390 (2022).","journal-title":"Sci. Rep."},{"key":"3057_CR190","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/s43588-021-00155-3","volume":"1","author":"JA Joseph","year":"2021","unstructured":"Joseph, J. A. et al. Physics-driven coarse-grained model for biomolecular phase separation with near-quantitative accuracy. Nat. Comput. Sci. 1, 732\u2013743 (2021).","journal-title":"Nat. Comput. Sci."},{"key":"3057_CR191","doi-asserted-by":"publisher","first-page":"e1012737","DOI":"10.1371\/journal.pcbi.1012737","volume":"21","author":"A Feito","year":"2025","unstructured":"Feito, A. et al. Benchmarking residue-resolution protein coarse-grained models for simulations of biomolecular condensates. PLoS Comput. Biol. 21, e1012737 (2025).","journal-title":"PLoS Comput. Biol."},{"key":"3057_CR192","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1039\/D1NJ04028F","volume":"46","author":"H Goel","year":"2022","unstructured":"Goel, H., Hazel, A., Yu, W., Jo, S. & MacKerell, A. D. Application of site-identification by ligand competitive saturation in computer-aided drug design. N. J. Chem. 46, 919\u2013932 (2022).","journal-title":"N. J. Chem."},{"key":"3057_CR193","doi-asserted-by":"publisher","first-page":"2600","DOI":"10.1021\/acs.molpharmaceut.3c00064","volume":"20","author":"AA Orr","year":"2023","unstructured":"Orr, A. A., Tao, A., Guvench, O. & MacKerell, A. D. Site-identification by ligand competitive saturation (SiLCS)-biologics approach for structure-based protein charge prediction. Mol. Pharm. 20, 2600\u20132611 (2023).","journal-title":"Mol. Pharm."},{"key":"3057_CR194","doi-asserted-by":"publisher","first-page":"315","DOI":"10.2174\/138620709787581701","volume":"12","author":"H Wan","year":"2009","unstructured":"Wan, H. & Holm\u00e9n, A. G. High throughput screening of physicochemical properties and in vitro ADME profiling in drug discovery. Comb. Chem. High Throughput Screen 12, 315\u2013329 (2009).","journal-title":"Comb. Chem. High Throughput Screen"},{"key":"3057_CR195","doi-asserted-by":"publisher","first-page":"13384","DOI":"10.3390\/molecules200713384","volume":"20","author":"LG Ferreira","year":"2015","unstructured":"Ferreira, L. G., Dos Santos, R. N., Oliva, G. & Andricopulo, A. D. Molecular docking and structure-based drug design strategies. Molecules 20, 13384\u201313421 (2015).","journal-title":"Molecules"},{"key":"3057_CR196","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.sbi.2017.10.010","volume":"48","author":"P \u015aled\u017a","year":"2018","unstructured":"\u015aled\u017a, P. & Caflisch, A. Protein structure-based drug design: from docking to molecular dynamics. Curr. Opin. Struct. Biol. 48, 93\u2013102 (2018).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"3057_CR197","doi-asserted-by":"publisher","first-page":"103241","DOI":"10.1016\/j.sbi.2026.103241","volume":"98","author":"A Pathak","year":"2026","unstructured":"Pathak, A., Tiwari, V. & Sowdhamini, R. Emerging strategies for computational identification of protein-protein interaction hotspots. Curr. Opin. Struct. Biol. 98, 103241 (2026).","journal-title":"Curr. Opin. Struct. Biol."},{"key":"3057_CR198","doi-asserted-by":"publisher","unstructured":"Shields, G. C. & Seybold, P. G. Computational Approaches for the Prediction of pKa Values https:\/\/doi.org\/10.1201\/b16128 (CRC Press, 2013)","DOI":"10.1201\/b16128"},{"key":"3057_CR199","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1016\/j.xphs.2020.10.051","volume":"110","author":"S Somani","year":"2021","unstructured":"Somani, S. et al. Toward biotherapeutics formulation composition engineering using site-identification by ligand competitive saturation (SILCS). J. Pharm. Sci. 110, 1103\u20131110 (2021).","journal-title":"J. Pharm. Sci."},{"key":"3057_CR200","doi-asserted-by":"publisher","first-page":"4323","DOI":"10.1021\/acs.molpharmaceut.0c00775","volume":"17","author":"S Jo","year":"2020","unstructured":"Jo, S., Xu, A., Curtis, J. E., Somani, S. & MacKerell, A. D. Computational characterization of antibody-excipient interactions for rational excipient selection using the site identification by ligand competitive saturation-biologics approach. Mol. Pharm. 17, 4323\u20134333 (2020).","journal-title":"Mol. Pharm."},{"key":"3057_CR201","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.jad.2024.10.010","volume":"369","author":"J Guo","year":"2025","unstructured":"Guo, J. et al. Interpretable machine learning model for predicting the prognosis of antibody positive autoimmune encephalitis patients. J. Affect. Disord. 369, 352\u2013363 (2025).","journal-title":"J. Affect. Disord."},{"key":"3057_CR202","doi-asserted-by":"publisher","first-page":"5847","DOI":"10.1021\/acs.jcim.5c00037","volume":"65","author":"L Angiolini","year":"2025","unstructured":"Angiolini, L. et al. Machine learning for predicting the drug-to-antibody ratio (DAR) in the synthesis of antibody-drug conjugates (ADCs). J. Chem. Inf. Model 65, 5847\u20135855 (2025).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR203","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41586-023-06415-8","volume":"620","author":"JL Watson","year":"2023","unstructured":"Watson, J. L. et al. De novo design of protein structure and function with RFdiffusion. Nature 620, 1089\u20131100 (2023).","journal-title":"Nature"},{"key":"3057_CR204","doi-asserted-by":"publisher","first-page":"2937","DOI":"10.1021\/ci400416e","volume":"53","author":"D Corrada","year":"2013","unstructured":"Corrada, D. & Colombo, G. Energetic and dynamic aspects of the affinity maturation process: characterizing improved variants from the bevacizumab antibody with molecular simulations. J. Chem. Inf. Model 53, 2937\u20132950 (2013).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR205","doi-asserted-by":"publisher","first-page":"6129","DOI":"10.1021\/acs.jcim.3c00947","volume":"63","author":"TM Prass","year":"2023","unstructured":"Prass, T. M., Garidel, P., Blech, M. & Sch\u00e4fer, L. V. Viscosity prediction of high-concentration antibody solutions with atomistic simulations. J. Chem. Inf. Model 63, 6129\u20136140 (2023).","journal-title":"J. Chem. Inf. Model"},{"key":"3057_CR206","doi-asserted-by":"publisher","first-page":"5508","DOI":"10.1021\/acs.jpcb.7b11800","volume":"122","author":"M Biswas","year":"2018","unstructured":"Biswas, M., Lickert, B. & Stock, G. Metadynamics enhanced Markov modeling of protein dynamics. J. Phys. Chem. B 122, 5508\u20135514 (2018).","journal-title":"J. Phys. Chem. B"},{"key":"3057_CR207","first-page":"205","volume":"350","author":"R Zhou","year":"2007","unstructured":"Zhou, R. Replica exchange molecular dynamics method for protein folding simulation. Methods Mol. Biol. 350, 205\u2013223 (2007).","journal-title":"Methods Mol. Biol."},{"key":"3057_CR208","doi-asserted-by":"publisher","first-page":"e1005659","DOI":"10.1371\/journal.pcbi.1005659","volume":"13","author":"P Eastman","year":"2017","unstructured":"Eastman, P. et al. OpenMM 7: Rapid development of high-performance algorithms for molecular dynamics. PLoS Comput. Biol. 13, e1005659 (2017).","journal-title":"PLoS Comput. Biol."},{"key":"3057_CR209","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/nrclinonc.2010.194","volume":"8","author":"A Ocana","year":"2010","unstructured":"Ocana, A., Pandiella, A., Siu, L. L. & Tannock, I. F. Preclinical development of molecular-targeted agents for cancer. Nat. Rev. Clin. Oncol. 8, 200\u2013209 (2010).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3057_CR210","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40495-025-00427-w","volume":"11","author":"P Chou","year":"2025","unstructured":"Chou, P. et al. Application of physiologically-based pharmacokinetic (PBPK) model in drug development and in dietary phytochemicals. Curr. Pharm. Rep. 11, 45 (2025).","journal-title":"Curr. Pharm. Rep."},{"key":"3057_CR211","unstructured":"Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody-drug conjugates - PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/30132210\/."},{"key":"3057_CR212","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/toxsci\/kfac101","volume":"191","author":"W-C Chou","year":"2023","unstructured":"Chou, W.-C. & Lin, Z. Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling. Toxicol. Sci. 191, 1\u201314 (2023).","journal-title":"Toxicol. Sci."},{"key":"3057_CR213","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s10928-025-09978-3","volume":"52","author":"H-P Chang","year":"2025","unstructured":"Chang, H.-P. & Shah, D. K. A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates. J. Pharmacokinet. Pharmacodyn. 52, 27 (2025).","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"3057_CR214","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.addr.2008.04.012","volume":"60","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. Adv. Drug Deliv. Rev. 60, 1421\u20131434 (2008).","journal-title":"Adv. Drug Deliv. Rev."},{"key":"3057_CR215","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0118977","volume":"10","author":"C Vasalou","year":"2015","unstructured":"Vasalou, C., Helmlinger, G. & Gomes, B. A mechanistic tumor penetration model to guide antibody drug conjugate design. PLoS One 10, e0118977 (2015).","journal-title":"PLoS One"},{"key":"3057_CR216","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/cts.12892","volume":"14","author":"J Weddell","year":"2021","unstructured":"Weddell, J., Chiney, M. S., Bhatnagar, S., Gibbs, J. P. & Shebley, M. Mechanistic modeling of intra-tumor spatial distribution of antibody-drug conjugates: insights into dosing strategies in oncology. Clin. Transl. Sci. 14, 395\u2013404 (2021).","journal-title":"Clin. Transl. Sci."},{"key":"3057_CR217","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1208\/s12248-016-9940-z","volume":"18","author":"C Cilliers","year":"2016","unstructured":"Cilliers, C., Guo, H., Liao, J., Christodolu, N. & Thurber, G. M. Multiscale modeling of antibody-drug conjugates: connecting tissue and cellular distribution to whole animal pharmacokinetics and potential implications for efficacy. AAPS J. 18, 1117\u20131130 (2016).","journal-title":"AAPS J."},{"key":"3057_CR218","first-page":"1288","volume":"63","author":"CP Graff","year":"2003","unstructured":"Graff, C. P. & Wittrup, K. D. Theoretical analysis of antibody targeting of tumor spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. 63, 1288\u20131296 (2003).","journal-title":"Cancer Res."},{"key":"3057_CR219","first-page":"5656","volume":"49","author":"K Fujimori","year":"1989","unstructured":"Fujimori, K., Covell, D. G., Fletcher, J. E. & Weinstein, J. N. Modeling analysis of the global and microscopic distribution of immunoglobulin G, F(ab\u2019)2, and Fab in tumors. Cancer Res. 49, 5656\u20135663 (1989).","journal-title":"Cancer Res."},{"key":"3057_CR220","first-page":"57","volume":"29","author":"GM Thurber","year":"2008","unstructured":"Thurber, G. M., Schmidt, M. M. & Wittrup, K. D. Factors determining antibody distribution in tumors. Trends Pharm. Sci. 29, 57\u201361 (2008).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR221","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1208\/s12248-019-0391-1","volume":"22","author":"B Menezes","year":"2020","unstructured":"Menezes, B., Cilliers, C., Wessler, T., Thurber, G. M. & Linderman, J. J. An agent-based systems pharmacology model of the antibody-drug conjugate Kadcyla to predict efficacy of different dosing regimens. AAPS J. 22, 29 (2020).","journal-title":"AAPS J."},{"key":"3057_CR222","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1007\/s11095-024-03715-0","volume":"41","author":"MC Calopiz","year":"2024","unstructured":"Calopiz, M. C., Linderman, J. J. & Thurber, G. M. Optimizing solid tumor treatment with antibody-drug conjugates using agent-based modeling: considering the role of a carrier dose and payload class. Pharm. Res. 41, 1109\u20131120 (2024).","journal-title":"Pharm. Res."},{"key":"3057_CR223","doi-asserted-by":"publisher","first-page":"3419","DOI":"10.3390\/cancers17213419","volume":"17","author":"N Sobhani","year":"2025","unstructured":"Sobhani, N. et al. AI-based cancer models in oncology: from diagnosis to ADC drug prediction. Cancers 17, 3419 (2025).","journal-title":"Cancers"},{"key":"3057_CR224","doi-asserted-by":"publisher","first-page":"e70190","DOI":"10.1002\/eji.70190","volume":"56","author":"O Goni","year":"2026","unstructured":"Goni, O., Kl\u00fcmper, N., Moreno, M. D. M. M., Eckstein, M. & Kuppe, C. Spatial multiomics reveal insights into ADC efficacy. Eur. J. Immunol. 56, e70190 (2026).","journal-title":"Eur. J. Immunol."},{"key":"3057_CR225","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2026.04.023","author":"ED Shulman","year":"2026","unstructured":"Shulman, E. D. et al. AI-predicted spatial transcriptomics unlocks breast cancer biomarkers from pathology. Cell https:\/\/doi.org\/10.1016\/j.cell.2026.04.023 (2026).","journal-title":"Cell"},{"key":"3057_CR226","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1459368","volume":"14","author":"Y Gao","year":"2024","unstructured":"Gao, Y. et al. Key considerations based on pharmacokinetic\/pharmacodynamic in the design of antibody-drug conjugates. Front. Oncol. 14, 1459368 (2024).","journal-title":"Front. Oncol."},{"key":"3057_CR227","doi-asserted-by":"publisher","first-page":"55126","DOI":"10.1021\/acsomega.5c09181","volume":"10","author":"C Nieto-Jim\u00e9nez","year":"2025","unstructured":"Nieto-Jim\u00e9nez, C. et al. Understanding the chemical characteristics of payloads and the expression of tumor-associated antigens of ADCs in clinical development. ACS Omega 10, 55126\u201355136 (2025).","journal-title":"ACS Omega"},{"key":"3057_CR228","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/toxics13070525","volume":"13","author":"R Zhang","year":"2025","unstructured":"Zhang, R., Wen, H., Lin, Z., Li, B. & Zhou, X. Artificial intelligence-driven drug toxicity prediction: advances, challenges, and future directions. Toxics 13, 525 (2025).","journal-title":"Toxics"},{"key":"3057_CR229","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1080\/17460441.2023.2273839","volume":"19","author":"M Bordukova","year":"2024","unstructured":"Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F. & Menden, M. P. Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opin. Drug Discov. 19, 33\u201342 (2024).","journal-title":"Expert Opin. Drug Discov."},{"key":"3057_CR230","unstructured":"Digital twins for cancer\u2014not if, but when, how, and why? | CBIIT. https:\/\/datascience.cancer.gov\/news-events\/blog\/digital-twins-cancer-not-if-when-how-and-why?."},{"key":"3057_CR231","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2026.105171","volume":"220","author":"DB Olawade","year":"2026","unstructured":"Olawade, D. B. et al. Digital twins in oncology: from predictive modelling to personalised treatment strategies. Crit. Rev. Oncol. Hematol. 220, 105171 (2026).","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"3057_CR232","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1002\/psp4.70122","volume":"14","author":"J Cort\u00e9s-R\u00edos","year":"2025","unstructured":"Cort\u00e9s-R\u00edos, J., Magee, M., Sher, A., Jusko, W. J. & Desikan, R. A step-by-step workflow for performing in silico clinical trials with nonlinear mixed effects models. CPT Pharmacomet. Syst. Pharm. 14, 1949\u20131964 (2025).","journal-title":"CPT Pharmacomet. Syst. Pharm."},{"key":"3057_CR233","unstructured":"Scientists develop a \u2018digital twin\u2019 model to predict cancer treatment responses\u2014The ASCO Post. https:\/\/ascopost.com\/news\/october-2024\/scientists-develop-a-digital-twin-model-to-predict-cancer-treatment-responses\/?."},{"key":"3057_CR234","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.3390\/pharmaceutics17111413","volume":"17","author":"Y Li","year":"2025","unstructured":"Li, Y., Sun, H. & Zhang, Z. The evolution and future directions of PBPK modeling in FDA regulatory review. Pharmaceutics 17, 1413 (2025).","journal-title":"Pharmaceutics"},{"key":"3057_CR235","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1002\/cpdd.1607","volume":"14","author":"AM Issa","year":"2025","unstructured":"Issa, A. M. Model-informed drug development in early-phase development: navigating complexity with quantitative clarity. Clin. Pharm. Drug Dev. 14, 738\u2013741 (2025).","journal-title":"Clin. Pharm. Drug Dev."},{"key":"3057_CR236","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1158\/1535-7163.MCT-16-0408","volume":"15","author":"F Loganzo","year":"2016","unstructured":"Loganzo, F., Sung, M. & Gerber, H.-P. Mechanisms of resistance to antibody-drug conjugates. Mol. Cancer Ther. 15, 2825\u20132834 (2016).","journal-title":"Mol. Cancer Ther."},{"key":"3057_CR237","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","volume":"18","author":"JZ Drago","year":"2021","unstructured":"Drago, J. Z., Modi, S. & Chandarlapaty, S. Unlocking the potential of antibody-drug conjugates for cancer therapy. Nat. Rev. Clin. Oncol. 18, 327\u2013344 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"3057_CR238","doi-asserted-by":"publisher","first-page":"7006","DOI":"10.1158\/1078-0432.CCR-17-0696","volume":"23","author":"M Sabbaghi","year":"2017","unstructured":"Sabbaghi, M. et al. Defective Cyclin B1 induction in trastuzumab-emtansine (T-DM1) acquired resistance in HER2-positive breast cancer. Clin. Cancer Res. 23, 7006\u20137019 (2017).","journal-title":"Clin. Cancer Res."},{"key":"3057_CR239","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.canlet.2019.11.026","volume":"470","author":"C R\u00edos-Luci","year":"2020","unstructured":"R\u00edos-Luci, C. et al. Adaptive resistance to trastuzumab impairs response to neratinib and lapatinib through deregulation of cell death mechanisms. Cancer Lett. 470, 161\u2013169 (2020).","journal-title":"Cancer Lett."},{"key":"3057_CR240","doi-asserted-by":"publisher","first-page":"4631","DOI":"10.3390\/cancers13184631","volume":"13","author":"L Gandullo-S\u00e1nchez","year":"2021","unstructured":"Gandullo-S\u00e1nchez, L., Oca\u00f1a, A. & Pandiella, A. Generation of antibody-drug conjugate resistant models. Cancers 13, 4631 (2021).","journal-title":"Cancers"},{"key":"3057_CR241","first-page":"2","volume":"9","author":"JS Roth","year":"2026","unstructured":"Roth, J. S. et al. Identification of antibody-drug conjugate payloads that are substrates of ATP-binding cassette drug efflux transporters. Cancer Drug Resist. 9, 2 (2026).","journal-title":"Cancer Drug Resist."},{"key":"3057_CR242","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-02000-1","volume":"27","author":"BA Lipert","year":"2025","unstructured":"Lipert, B. A. et al. CRISPR screens with trastuzumab emtansine in HER2-positive breast cancer cell lines reveal new insights into drug resistance. Breast Cancer Res. 27, 48 (2025).","journal-title":"Breast Cancer Res."},{"key":"3057_CR243","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41589-019-0342-2","volume":"15","author":"CK Tsui","year":"2019","unstructured":"Tsui, C. K. et al. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity. Nat. Chem. Biol. 15, 949\u2013958 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"3057_CR244","doi-asserted-by":"publisher","first-page":"670","DOI":"10.3390\/cancers12030670","volume":"12","author":"M Nadal-Serrano","year":"2020","unstructured":"Nadal-Serrano, M. et al. The second generation antibody-drug conjugate SYD985 overcomes resistances to T-DM1. Cancers 12, 670 (2020).","journal-title":"Cancers"},{"key":"3057_CR245","unstructured":"Mechanisms of acquired resistance to trastuzumab emtansine in breast cancer cells\u2014PubMed. https:\/\/pubmed.ncbi.nlm.nih.gov\/29695635\/."},{"key":"3057_CR246","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1016\/j.tips.2018.09.003","volume":"39","author":"A Oca\u00f1a","year":"2018","unstructured":"Oca\u00f1a, A., Garc\u00eda-Alonso, S., Amir, E. & Pandiella, A. Refining early antitumoral drug development. Trends Pharm. Sci. 39, 922\u2013925 (2018).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR247","doi-asserted-by":"publisher","first-page":"15893","DOI":"10.1021\/acs.jmedchem.2c01579","volume":"65","author":"AD Hobson","year":"2022","unstructured":"Hobson, A. D. et al. Discovery of ABBV-3373, an anti-TNF glucocorticoid receptor modulator immunology antibody drug conjugate. J. Med. Chem. 65, 15893\u201315934 (2022).","journal-title":"J. Med. Chem."},{"key":"3057_CR248","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"F Buttgereit","year":"2023","unstructured":"Buttgereit, F. et al. Efficacy and safety of ABBV-3373, a novel anti-tumor necrosis factor glucocorticoid receptor modulator antibody-drug conjugate, in adults with moderate-to-severe rheumatoid arthritis despite methotrexate therapy: a randomized, double-blind, active-controlled proof-of-concept phase IIa trial. Arthritis Rheumatol. 75, 879\u2013889 (2023).","journal-title":"Arthritis Rheumatol."},{"key":"3057_CR249","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add8936","volume":"16","author":"MJ McPherson","year":"2024","unstructured":"McPherson, M. J. et al. An anti-TNF-glucocorticoid receptor modulator antibody-drug conjugate is efficacious against immune-mediated inflammatory diseases. Sci. Transl. Med. 16, eadd8936 (2024).","journal-title":"Sci. Transl. Med."},{"key":"3057_CR250","doi-asserted-by":"publisher","first-page":"11761","DOI":"10.3390\/ijms262311761","volume":"26","author":"Q Du","year":"2025","unstructured":"Du, Q. et al. CD74-Targeting antibody-drug conjugate enhances immunosuppression of glucocorticoid in systemic lupus erythematosus. Int. J. Mol. Sci. 26, 11761 (2025).","journal-title":"Int. J. Mol. Sci."},{"key":"3057_CR251","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s13075-024-03452-0","volume":"26","author":"T Dixit","year":"2024","unstructured":"Dixit, T., Vaidya, A. & Ravindran, S. Therapeutic potential of antibody-drug conjugates possessing bifunctional anti-inflammatory action in the pathogenesis of rheumatoid arthritis. Arthritis Res. Ther. 26, 216 (2024).","journal-title":"Arthritis Res. Ther."},{"key":"3057_CR252","doi-asserted-by":"publisher","first-page":"e51233","DOI":"10.1002\/eji.202451233","volume":"55","author":"A Gjurgjaj","year":"2025","unstructured":"Gjurgjaj, A. & Conde, C. D. Narrowing down key players in autoimmunity via single-cell multiomics. Eur. J. Immunol. 55, e51233 (2025).","journal-title":"Eur. J. Immunol."},{"key":"3057_CR253","doi-asserted-by":"publisher","first-page":"1628120","DOI":"10.3389\/fimmu.2025.1628120","volume":"16","author":"Y Zhu","year":"2025","unstructured":"Zhu, Y., Anania, V. G., Lill, J. R. & Modrusan, Z. Editorial: Revolutionizing immunological disease understanding through single-cell multi-omics technologies. Front. Immunol. 16, 1628120 (2025).","journal-title":"Front. Immunol."},{"key":"3057_CR254","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.neuroscience.2025.12.053","volume":"596","author":"M AmeliMojarad","year":"2026","unstructured":"AmeliMojarad, M. & AmeliMojarad, M. Antibody drug conjugates in Alzheimer\u2019s disease: emerging strategies and future directions. Neuroscience 596, 45\u201353 (2026).","journal-title":"Neuroscience"},{"key":"3057_CR255","unstructured":"A brain-shuttled antibody targeting alpha synuclein aggregates for the treatment of synucleinopathies | npj Parkinson\u2019s Disease. https:\/\/www.nature.com\/articles\/s41531-025-01117-6."},{"key":"3057_CR256","doi-asserted-by":"publisher","DOI":"10.1002\/alz.091477","volume":"20","author":"S Nampally","year":"2024","unstructured":"Nampally, S. et al. A new class of neurodegenerative disease-fighting drugs: morADC (Morphomer\u00aeAntib. drug conjugates). Alzheimer\u2019s. Dement. 20, e091477 (2024).","journal-title":"Alzheimer\u2019s. Dement."},{"key":"3057_CR257","unstructured":"Waldron, J. Lilly pays AC Immune $12.5M to expand Alzheimer\u2019s collab. https:\/\/www.fiercebiotech.com\/biotech\/lilly-pays-ac-immune-125m-expand-alzheimers-collab-small-molecule-draws-closer-clinic (2026)."},{"key":"3057_CR258","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s11095-025-03828-0","volume":"42","author":"B G\u00fclave","year":"2025","unstructured":"G\u00fclave, B. et al. Prediction of the extent of blood-brain barrier transport using machine learning and integration into the LeiCNS-PK3.0 model. Pharm. Res. 42, 281\u2013289 (2025).","journal-title":"Pharm. Res."},{"key":"3057_CR259","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.tips.2025.08.006","volume":"46","author":"H Baghirov","year":"2025","unstructured":"Baghirov, H. Beyond the blood-brain barrier: the fate of transcytosed therapeutics. Trends Pharm. Sci. 46, 946\u2013957 (2025).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR260","doi-asserted-by":"publisher","first-page":"5901","DOI":"10.1093\/nar\/gkad415","volume":"51","author":"B Malecova","year":"2023","unstructured":"Malecova, B. et al. Targeted tissue delivery of RNA therapeutics using antibody-oligonucleotide conjugates (AOCs). Nucleic Acids Res. 51, 5901\u20135910 (2023).","journal-title":"Nucleic Acids Res."},{"key":"3057_CR261","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1038\/nature16057","volume":"527","author":"SM Lehar","year":"2015","unstructured":"Lehar, S. M. et al. Novel antibody-antibiotic conjugate eliminates intracellular S. aureus. Nature 527, 323\u2013328 (2015).","journal-title":"Nature"},{"key":"3057_CR262","doi-asserted-by":"publisher","first-page":"e02588","DOI":"10.1128\/AAC.02588-18","volume":"63","author":"M Peck","year":"2019","unstructured":"Peck, M. et al. A phase 1, randomized, single-ascending-dose study to investigate the safety, tolerability, and pharmacokinetics of DSTA4637S, an anti-staphylococcus aureus thiomab antibody-antibiotic conjugate, in healthy volunteers. Antimicrob. Agents Chemother. 63, e02588\u201318 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"3057_CR263","doi-asserted-by":"publisher","first-page":"1807","DOI":"10.3390\/pharmaceutics15071807","volume":"15","author":"LB Pal","year":"2023","unstructured":"Pal, L. B., Bule, P., Khan, W. & Chella, N. An overview of the development and preclinical evaluation of antibody-drug conjugates for non-oncological applications. Pharmaceutics 15, 1807 (2023).","journal-title":"Pharmaceutics"},{"key":"3057_CR264","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1016\/j.tips.2025.10.005","volume":"46","author":"Y Wang","year":"2025","unstructured":"Wang, Y., Guo, C. & Li, W. Artificial intelligence in antibody-drug conjugate development. Trends Pharm. Sci. 46, 1209\u20131223 (2025).","journal-title":"Trends Pharm. Sci."},{"key":"3057_CR265","doi-asserted-by":"publisher","DOI":"10.1002\/wcms.70049","volume":"15","author":"A Lavecchia","year":"2025","unstructured":"Lavecchia, A. Explainable artificial intelligence in drug discovery: bridging predictive power and mechanistic insight. WIREs Comput. Mol. Sci. 15, e70049 (2025).","journal-title":"WIREs Comput. Mol. Sci."},{"key":"3057_CR266","doi-asserted-by":"publisher","unstructured":"Kim, Y. et al. Medical hallucination in foundation models and their impact on healthcare. Preprint at https:\/\/doi.org\/10.1101\/2025.02.28.25323115 (2025).","DOI":"10.1101\/2025.02.28.25323115"},{"key":"3057_CR267","doi-asserted-by":"publisher","first-page":"217821","DOI":"10.1016\/j.canlet.2025.217821","volume":"627","author":"S Sarvepalli","year":"2025","unstructured":"Sarvepalli, S. & Vadarevu, S. Role of artificial intelligence in cancer drug discovery and development. Cancer Lett. 627, 217821 (2025).","journal-title":"Cancer Lett."},{"key":"3057_CR268","unstructured":"Research, C. for D. E. and. Considerations for the use of artificial intelligence to support regulatory decision-making for drug and biological products. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological (2025)."},{"key":"3057_CR269","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s42256-025-00991-2","volume":"7","author":"T Hanser","year":"2025","unstructured":"Hanser, T. et al. Data-driven federated learning in drug discovery with knowledge distillation. Nat. Mach. Intell. 7, 423\u2013436 (2025).","journal-title":"Nat. Mach. Intell."},{"key":"3057_CR270","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1016\/j.annonc.2026.01.009","volume":"37","author":"S-D Hong","year":"2026","unstructured":"Hong, S.-D. et al. Izalontamab brengitecan (Iza-bren; BL-B01D1), a first-in-class EGFR-HER3 bispecific antibody\u2013drug conjugate, for patients with EGFR-mutated NSCLC: pooled analysis of phase I and phase II trials. Ann. Oncol. 37, 813\u2013824 (2026).","journal-title":"Ann. Oncol."},{"key":"3057_CR271","doi-asserted-by":"publisher","first-page":"2235","DOI":"10.1016\/S0140-6736(25)01954-3","volume":"406","author":"Y Yang","year":"2025","unstructured":"Yang, Y. et al. Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China. Lancet 406, 2235\u20132243 (2025).","journal-title":"Lancet"},{"key":"3057_CR272","first-page":"tbad014.009","volume":"6","author":"P Wang","year":"2023","unstructured":"Wang, P., Guo, K., Peng, J., Sun, J. & Xu, T. JSKN003, a novel biparatopic anti-HER2 antibody-drug conjugate, exhibits potent antitumor efficacy. Antib. Ther. 6, tbad014.009 (2023).","journal-title":"Antib. Ther."},{"key":"3057_CR273","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1200\/JCO.2026.44.16_suppl.1123","volume":"44","author":"H Yao","year":"2026","unstructured":"Yao, H. et al. JSKN016, a first-in-class anti-TROP2\/HER3 bispecific antibody-drug conjugate (ADC), in patients (pts) with HER2-negative locally advanced or metastatic breast cancer: Results from a phase I study. J. Clin. Oncol. 44, 1123\u20131123 (2026).","journal-title":"J. Clin. Oncol."},{"key":"3057_CR274","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1200\/JCO-25-01153","volume":"44","author":"J-J Li","year":"2026","unstructured":"Li, J.-J. et al. Efficacy and safety of neoadjuvant TQB2102 in locally advanced or early human epidermal growth factor receptor 2-positive breast cancer: a randomized, open-label, multicenter, phase II trial. J. Clin. Oncol. 44, 20\u201330 (2026).","journal-title":"J. Clin. Oncol."},{"key":"3057_CR275","doi-asserted-by":"publisher","first-page":"5736","DOI":"10.1158\/1538-7445.AM2023-5736","volume":"83","author":"F Comer","year":"2023","unstructured":"Comer, F. et al. Abstract 5736: AZD9592: an EGFR-cMET bispecific antibody-drug conjugate (ADC) targeting key oncogenic drivers in non-small-cell lung cancer (NSCLC) and beyond. Cancer Res. 83, 5736 (2023).","journal-title":"Cancer Res."},{"key":"3057_CR276","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1158\/1535-7163.MCT-21-0009","volume":"20","author":"JO DaSilva","year":"2021","unstructured":"DaSilva, J. O. et al. A biparatopic antibody-drug conjugate to treat MET-expressing cancers, including those that are unresponsive to MET pathway blockade. Mol. Cancer Ther. 20, 1966\u20131976 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"3057_CR277","doi-asserted-by":"publisher","first-page":"2890","DOI":"10.1158\/1538-7445.AM2020-2890","volume":"80","author":"O Ab","year":"2020","unstructured":"Ab, O. et al. Abstract 2890: IMGN151\u2014a next generation folate receptor alpha targeting antibody drug conjugate active against tumors with low, medium and high receptor expression. Cancer Res. 80, 2890 (2020).","journal-title":"Cancer Res."},{"key":"3057_CR278","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1158\/1078-0432.CCR-25-0634","volume":"31","author":"C Li","year":"2025","unstructured":"Li, C. et al. Preclinical Evaluation of DB-1419, a novel bifunctional and bispecific anti-B7-H3 \u00d7 PD-L1 antibody-drug conjugate. Clin. Cancer Res. 31, 3581\u20133593 (2025).","journal-title":"Clin. Cancer Res."},{"key":"3057_CR279","doi-asserted-by":"publisher","first-page":"5284","DOI":"10.1158\/1538-7445.AM2022-5284","volume":"82","author":"C Knuehl","year":"2022","unstructured":"Knuehl, C. et al. Abstract 5284: M1231 is a bispecific anti-MUC1xEGFR antibody-drug conjugate designed to treat solid tumors with MUC1 and EGFR co-expression. Cancer Res. 82, 5284 (2022).","journal-title":"Cancer Res."},{"key":"3057_CR280","doi-asserted-by":"publisher","first-page":"S749","DOI":"10.1016\/j.annonc.2022.07.589","volume":"33","author":"K Jhaveri","year":"2022","unstructured":"Jhaveri, K. et al. 460MO Preliminary results from a phase I study using the bispecific, human epidermal growth factor 2 (HER2)-targeting antibody-drug conjugate (ADC) zanidatamab zovodotin (ZW49) in solid cancers. Ann. Oncol. 33, S749\u2013S750 (2022).","journal-title":"Ann. Oncol."},{"key":"3057_CR281","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1158\/1535-7163.MCT-20-0014","volume":"20","author":"MD Pegram","year":"2021","unstructured":"Pegram, M. D. et al. First-in-human, phase 1 dose-escalation study of biparatopic anti-HER2 antibody-drug conjugate MEDI4276 in patients with HER2-positive advanced breast or gastric cancer. Mol. Cancer Ther. 20, 1442\u20131453 (2021).","journal-title":"Mol. Cancer Ther."},{"key":"3057_CR282","doi-asserted-by":"publisher","DOI":"10.15252\/msb.20178124","volume":"14","author":"R Argelaguet","year":"2018","unstructured":"Argelaguet, R. et al. Multi-Omics factor analysis\u2014a framework for unsupervised integration of multi-omics data sets. Mol. Syst. Biol. 14, e8124 (2018).","journal-title":"Mol. Syst. Biol."},{"key":"3057_CR283","doi-asserted-by":"publisher","DOI":"10.1186\/s13059-017-1215-1","volume":"18","author":"Y Hasin","year":"2017","unstructured":"Hasin, Y., Seldin, M. & Lusis, A. Multi-omics approaches to disease. Genome Biol. 18, 83 (2017).","journal-title":"Genome Biol."},{"key":"3057_CR284","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41587-019-0036-z","volume":"37","author":"JJ Almagro Armenteros","year":"2019","unstructured":"Almagro Armenteros, J. J. et al. SignalP 5.0 improves signal peptide predictions using deep neural networks. Nat. Biotechnol. 37, 420\u2013423 (2019).","journal-title":"Nat. Biotechnol."},{"key":"3057_CR285","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1093\/bioinformatics\/btx431","volume":"33","author":"JJ Almagro Armenteros","year":"2017","unstructured":"Almagro Armenteros, J. J., S\u00f8nderby, C. K., S\u00f8nderby, S. K., Nielsen, H. & Winther, O. DeepLoc: prediction of protein subcellular localization using deep learning. Bioinformatics 33, 3387\u20133395 (2017).","journal-title":"Bioinformatics"},{"key":"3057_CR286","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41588-020-00726-6","volume":"52","author":"GS Kinker","year":"2020","unstructured":"Kinker, G. S. et al. Pan-cancer single-cell RNA-seq identifies recurring programs of cellular heterogeneity. Nat. Genet. 52, 1208\u20131218 (2020).","journal-title":"Nat. Genet."},{"key":"3057_CR287","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1126\/science.abj8754","volume":"373","author":"M Baek","year":"2021","unstructured":"Baek, M. et al. Accurate prediction of protein structures and interactions using a three-track neural network. Science 373, 871\u2013876 (2021).","journal-title":"Science"},{"key":"3057_CR288","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/s41592-019-0666-6","volume":"17","author":"P Gainza","year":"2020","unstructured":"Gainza, P. et al. Deciphering interaction fingerprints from protein molecular surfaces using geometric deep learning. Nat. Methods 17, 184\u2013192 (2020).","journal-title":"Nat. Methods"},{"key":"3057_CR289","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38063-x","volume":"14","author":"JA Ruffolo","year":"2023","unstructured":"Ruffolo, J. A., Chu, L.-S., Mahajan, S. P. & Gray, J. J. Fast, accurate antibody structure prediction from deep learning on massive set of natural antibodies. Nat. Commun. 14, 2389 (2023).","journal-title":"Nat. Commun."},{"key":"3057_CR290","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-32007-7","volume":"13","author":"N Ferruz","year":"2022","unstructured":"Ferruz, N., Schmidt, S. & H\u00f6cker, B. ProtGPT2 is a deep unsupervised language model for protein design. Nat. Commun. 13, 4348 (2022).","journal-title":"Nat. Commun."},{"key":"3057_CR291","doi-asserted-by":"publisher","first-page":"e1005962","DOI":"10.1371\/journal.pcbi.1005962","volume":"14","author":"D Westergaard","year":"2018","unstructured":"Westergaard, D., St\u00e6rfeldt, H.-H., T\u00f8nsberg, C., Jensen, L. J. & Brunak, S. A comprehensive and quantitative comparison of text-mining in 15 million full-text articles versus their corresponding abstracts. PLoS Comput. Biol. 14, e1005962 (2018).","journal-title":"PLoS Comput. Biol."},{"key":"3057_CR292","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1093\/bioinformatics\/btz682","volume":"36","author":"J Lee","year":"2020","unstructured":"Lee, J. et al. BioBERT: a pre-trained biomedical language representation model for biomedical text mining. Bioinformatics 36, 1234\u20131240 (2020).","journal-title":"Bioinformatics"}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03057-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03057-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:05:25Z","timestamp":1790172325000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-03057-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":292,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3057"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-03057-w","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,23]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.O. Consultant fee from NMS. Former consultant of Servier, WWIT, and CancerAppy. Former employee of Symphogen. A.O and J.R.E are co-founders of WBT HK. No competing interests to declare in relation to this work.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"401"}}